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ABSTRACT 
 
Solid organ transplantation is considered the treatment of choice for many end-stage organ 
diseases, resulting in marked improvements in both morbidity and mortality. Thus far, short term 
results are excellent, with patient survival rates greater than 90% one year after surgery, but there 
are several problems with the long term acceptance and the use of immunosuppressive drugs 
causing infections, organ failure and cancer.  
Hematopoietic Stem Cells Transplantation (HSCT) is an established procedure concerning the 
infusion of autologous, syngenic or allogeneic stem cells to re-establish acquired and congenital 
disorders of the hematopoietic system. The success of allogeneic HSCT therapy depends on a 
multitude of parameters, including the type and stage of the underlying disease, patient age, 
genetic disparity between donor/host, type and intensity of the pre-transplantation conditioning 
regimen. The main side effect of HSCT is the Graft versus Host Disease (GvHD) where donor T 
cells can cause pathology involving the damage of host tissues. Patients undergoing acute or 
chronic GvHD receive immunosuppressive regimen that is responsible for several side effects. 
In summary, the use of immunosuppressive drugs in the setting of solid organ transplantation 
and GvHD has markedly reduced the incidence of acute rejection and the tissue damage in 
GvHD. However, the numerous adverse side effects observed, and failure to effectively prevent 
chronic allograft dysfunction of conventional immunosuppression boost the development of 
alternative strategies to avoid graft rejection and for the treatment of GvHD.  
To this aim, the use of CD4+CD25+FOXP3+ regulatory T cells (Treg) as a cellular therapy 
is an attractive approach for autoimmunity disease, GvHD and for limiting immune responses to 
allograft after transplantation. Treg have a pivotal role in maintaining peripheral immunological 
tolerance, by preventing autoimmunity and chronic inflammation. Animal models have shown 
how the infusion of freshly isolated or expanded Treg can prevent graft versus host disease 
(GvHD) and both acute and chronic organ rejection after transplantation. In humans, a few 
clinical studies have been published reporting the infusion of Treg for the prevention of GvHD 
and autoimmune disease (Type I diabetes). These are phase-I trials showing safety, but there are 
no published results testing the efficacy of Treg in solid organ transplantation. 
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Results of my thesis are divided in three chapters, the first provides the characterization and 
cell processing of Tregs from healthy controls and patients, the second details the ex vivo 
expansion of freshly isolated Treg from healthy donors and patients in a waiting list for liver 
transplantation, followed by the investigation of the impact of the main immunosuppressive 
drugs on viability, proliferative capacity and function of Treg after expansion.     
In the first chapter, peripheral blood Treg were enumerated to assess the suitable circulating 
cells and then isolated for functional characterization. Studied patients have a slightly lower Treg 
number comparing to healthy donor however cells are functional after in vitro analysis.         
In the second chapter, it has been developed a protocol, using reagents compatible with Good 
Manufacture Practices, for the expansion of clinically useful number of functional suppressive 
Treg cells. CD4+CD25+ T cells were expanded ex vivo using rapamycin and then characterized 
in vitro. After expansion it was possible to recover a high Treg number suitable for the infusion 
of more than 3x10
6
 cells/Kg, moreover, these cells highly express FOXP3 and are highly 
suppressive in vitro.  
Since ex vivo expanded Treg will be used in a phase I/II clinical trial for promoting allograft 
tolerance after organ transplantation and for GvHD treatment, the immunosuppressive regimen is 
still maintained. To date, there are no data showing the effect of these drugs on Treg preparation. 
To better understand the suitable procedure of Treg infusion, the third chapter of this study 
investigates the impact of Tacrolimus, Micophenolate-Mofetil and Methyl-Prednisolone on 
viability, proliferative capacity and function of ex vivo expanded Treg. Results obtained in vitro 
suggest that although immunosuppressive drugs influence the viability of Tregs, their phenotype 
and mostly suppressive ability is not altered.  
At the end it is possible to conclude that ex vivo expansion is necessary to infuse a high Treg 
dose and although many other factors in vivo can contribute to the success of Treg therapy, the 
infusion of Tregs during the administration of the highest dose of immunosuppressants should be 
carefully considered. 
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GENERAL INTRODUCTION 
 
 
1.  Targets for cell therapy  
 
1.1  Solid organ transplantation 
 
Solid organ transplantation (SOT) is defined as the artificial transfer of tissues or organs 
from one individual to another. To date, it is considered the treatment of choice for many end-
organ diseases, resulting in marked improvements in both morbidity and mortality. In recent 
decades, transplantation has saved the lives of thousands of people who otherwise were 
condemned to death because of their life-threatening diseases. The first successful 
transplantation of a liver in a human was performed by Thomas Starzl in 1967 and 20 years later 
liver transplantation was declared as an accepted therapy for end-stage liver disease. The 
principal indications for liver transplantation in Europe are cirrhosis, cancer, cholestatic diseases 
and acute hepatic failure. Short term survival is excellent, with patient survival rates greater than 
90% one year after surgery, but there are several problem with the long term acceptance and the 
use of immunosuppresive drugs causing infections, organ failure and cancer.  However, 
comparing this to other solid organs such as the heart or kidney, the liver is an immune 
privileged organ with a lower incidence of graft rejection. In addition, liver transplants do not 
require HLA matching of donor to recipients, and it is estimated that about one third of liver 
transplant recipients with stable function can be totally withdrawn from immunesuppression
1
. 
Unfortunately the identification of stable patients suitable for withdrawal is complex, and 
therefore lifelong treatment with immunosuppressive drugs (ID) is required in the majority of 
patients in order to prevent rejection of the liver graft. 
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1.2  Graft Rejection 
 
The graft can be syngeneic (between identical individuals like twins) or autologous (auto-
transplant). In this situation the recipient is fully tolerant to the transplant and accepts it without 
a rejection phenomenon. Where there is histo-incompatibility, an immune response is elicited 
against the foreign antigens, the magnitude of which determines acceptance or rejection of the 
transplanted organ. The response to transplanted organ follows a two step process. 
“Allorecognition” where the transplanted allogeneic tissues are recognised by the host and the 
“alloresponse” concerning the effector mechanisms recruited in the reaction to the foreign tissue 
and the outcome of those effects. To better understand the allorecognition's process it's important 
to introduce the histocompatibility  antigens, a group of 
genetically determined proteins on the surface of cell membranes that serve to identify a cell as 
self or non-self. They can be divided in two groups, major and minor, (MHC and mHAg 
respectively), based on the strength of recipient immune responses engendered by their 
expression on histo-incompatible tissues.  
MHC are codificated on the short arm of chromosome 6 and can be divided into two classes 
(MHC I and II). MHC class I molecules consist of one membrane-spanning α chain (heavy 
chain), and one β chain (light chain) while  MHC class II present two membrane-spanning 
chains, α and β, of similar size.  In each case, the MHC molecule has a groove that binds a 
peptide, essential for the interaction with T cells and the immune response starting. The two 
classes of MHC proteins differ not only in their structure, but more importantly in their 
functional roles within the immune system since they are specialised to present different types of 
antigens, thereby eliciting different responses. MHC I are located on almost every cell in the 
body and present endogenous antigens originating from the cytoplasm.  They present self-
proteins, but also viral proteins. Once degraded, the peptide fragments are transported to the 
endoplasmic reticulum, where they can bind to MHC I proteins, before being transported via the 
Golgi apparatus to the cell surface.  Once at the cell surface, the membrane-bound MHC I 
protein displays the antigen for recognition by special immune cells known as cytotoxic T cell 
lymphocytes. MHC II glycoproteins are only present on specialised antigen-presenting cells 
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(APC), like macrophages, dendritic and B cells.  MHC II proteins present exogenous antigens 
originating extracellularly. APCs degrade proteins from bacteria and pathogens sequestering 
these fragments into the endosome so they can be bound to MHC II proteins, before the 
expression on the cell surface.  Once on the cell surface, the membrane-bound MHC II protein 
displays the antigen for recognition to the helper T lymphocyte (T helper).  HLA-A, B and C are 
the most important MHC-I protein since their products have been well defined as "classical 
transplantation antigens". Others human class I genes that show sequence homology to classical 
loci include HLA-E, F, G, H, and a set of five MIC (MHC class I related) genes (MIC A–E). The 
principal MHC class II proteins consist of six subregions, termed DR, DQ, DP, DO, DN and 
DM. 
Minor histocompatibility antigens are polymorphic peptides consisting of 9–12 amino acids 
encoded by either autosomal chromosomes or Y-chromosomes. mHAg are recognised by T cells 
only after the binding to the antigen recognition site of MHC molecules. Thus the occurrence of 
mHag depends on the presence of specific HLA antigens, which is called the MHC restriction. 
To date, 28 mHAg have been identified, 18 encoded by autosomal and 10 by Y-chromosomes. 
On the basis of their tissutal distribution it is possible to find restricted and broad mHag. Most of 
mHAg encoded by Y-chromosome are present in most tissues, including those crucial for 
GVHD: skin, intestines, and liver
2
. Most of autosomal and 2 MiHAs encoded by Y-chromosome 
(B8/HY and B52/HY) appear only in hematologic cells including leukemic cells, dendritic cells, 
NK, and multiple myeloma cells. Thanks to their restricted distribution all of them may be 
potentially exploited in immunotherapy.  
Allorecognition can proceed via three non-mutually exclusive and concurrent mechanisms 
(Figure 1):  
1. direct allorecognition, whereby T cells recognise determinants on intact donor MHC 
molecules displayed on the surface of transplanted cells ;  
2. indirect3 allorecognition in which donor MHC molecules are processed and presented as 
peptides by self-MHC  
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3.  semi-direct allorecognition where trafficking recipient dendritic cells DCs acquire intact 
donor MHC:peptide complexes from cells of the graft enabling them to stimulate 
antigen-specific immune responses with both direct and indirect allospecificities
4
.  
 
 
Figure 1 Alloantigen presentation. A) Alloantigen presentation via the direct, semi-direct 
and indirect pathways following organ transplantation, and  B) the relative intensity of each 
antigen-presentation pathway during the post-transplantation (post-Tx) period. From Sagoo et 
al
5
.  
 
Direct allorecognition was long believed to be the only mechanism by which allogeneic 
antigens could be recognised in the donor graft. This mechanism explain how recipient T cells 
recognise determinants on intact donor MHC-peptide complexes displayed on the surface of 
transplanted cells
6
. This was demonstrated in vitro by a mixed lymphocyte reaction or in vivo 
using Rag-/- MHC class II-/- mice reconstituted with syngeneic CD4
+
 T cells. In this setting 
mice do not present the capacity to present the antigen via indirect mechanism but they are able 
to reject cardiac allografts
7
. Under the influence of pro-inflammatory signals engendered by the 
transplantation procedure, donor DCs traffic to secondary lymphoid tissues of the recipient 
12 
 
initiating a direct responses. To date, as well reviewed by Archbold et al
8
,  there are two non-
mutually exclusive theories that further delineate the molecular characteristics of the high 
frequency of direct alloreactivity, the “high determinant density” and the “multiple binary 
complex” models which differ on whether alloreactive T cells directly recognise polymorphisms 
in allogeneic MHC or presented peptide in the MHC peptide binding groove. The first one 
explains how T cells are directly able to recognise the exposed polymorphic residues on 
allogeneic MHC, thus consigning the bound peptide to secondary importance, whilst the latter 
one proposes that recognition of peptide bound by allogeneic MHC is of primary importance to 
direct allorecognition in a manner akin to conventional self-restricted responses.  It is likely that 
both mechanisms contribute to direct allorecognition, the overall contribution of each being 
related to the site and magnitude of the structural differences in MHC molecules between 
responder and stimulator cells. Where the allogeneic MHC is structurally very disparate from 
responder MHC, the alloresponse may be directed against residues on the MHC itself whereas 
where self and foreign MHC are closely matched, the focus of the alloreactivity may be directed 
towards epitopes of endogenous peptides that are displayed by stimulator but not by responder 
MHC molecules
9
.  
The indirect pathway of allorecognition refers to identification of processed peptides of 
allogeneic antigens presented by self-MHC in a self-restricted manner
3
 (Figure 1). Indirect 
alloantigen presentation results in alloresponses dominated by CD4
+
 T cells. The requirement for 
antigen processing in the indirect pathway, despite considerable amplification of this response, 
naturally correlates with slower responses than those engendered via the direct pathway. 
Additionally, the lower frequency of T cells in the normal repertoire with indirect compared to 
direct allospecificity
10
 suggests that the direct response dominates the early post-transplant 
period while the indirect pathway plays a role in long term alloantigen presentation when the 
donor APC has been exhausted
11
. Although there is significant evidence in support of this 
assertion, it is important to note that in the absence of direct responses, the indirect pathway 
alone can also result in rapid acute graft rejection
12
. As showed by Auchincloss et al
12
, MHC 
class I knock out recipient mice could reject skin grafts from MHC class II knock out donor 
mice. The recipient mice lacked CD8
+
 cytotoxic T cells capable of recognising donor MHC class 
I molecules directly, and the CD4
+
 T cells in the recipient animals could only be stimulated by 
13 
 
recognising donor MHC class I molecules indirectly, presented in the context of recipient MHC 
class II molecules.  
Recently it was discovered that another pathway of allorecognition could provide an 
alternative explanation for previously published observations. For example, reports of MHC 
class II deficient recipients rejecting co-stimulation deficient (CD80-/-CD86-/-) allogeneic 
cardiac grafts as rapidly as wild-type transplants13 could be attributed to semi-direct presentation 
of MHC from the graft rather than to trans co-stimulation. Semi-direct presentation provide cell-
to-cell contact between donor and recipient APC. This interaction may transfer intact membrane 
components including intact allo-MHC. Likewise, donor APC can release exosomes containing 
intact MHC which fuse with the membrane of recipient APCs. The site of MHC transfer is 
unknown and may occur either within the graft or within regional lymph nodes. If MHC transfer 
occurs in lymph nodes, it will be between donor and recipient DC but, if within tissues, transfer 
will be between a non-professional-APC and DC. Recipient APCs, now chimeric for MHC, 
stimulate direct pathway CD4 and CD8 responses through intact foreign MHC and indirect 
responses through processing and presentation of peptides of foreign MHC acquired from 
necrotic and apoptotic cell material. Given that the same APC stimulates both CD4 and CD8 
 
1.3  Hematopoietic Stem Cells Transplantation (HSCT) 
 
HSCT  is an established procedure concerning the infusion of autologous, syngenic or 
allogeneic stem cells to re-establish acquired and congenital disorders of the hematopoietic 
system, including disorders of the immune system, and enzyme replacement in metabolic 
disorders. In Europe, 661 of 680 centres in 48 countries reported 37 818 HSCT in 33 678 patients 
(42% allogeneic and 58% autologous) in the 2013 survey. Main indications are leukaemia, 
lymphoid neoplasias, solid tumors, and nonmalignant disorders14. 
The success of allogeneic HSCT therapy depends on a multitude of parameters, including the 
type and stage of the underlying disease, patient age, genetic disparity between donor/host, type 
and intensity of the pre-transplantation conditioning regimen, and the presence of transplant-
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related toxicities. HSCT usually first undergo a conditioning regime that can include 
chemotherapy and/or radiation and/or T cell depleting antibodies15. This conditioning regime 
eradicates the recipient’s own T and B cells leaving the recipient highly immuno-compromised 
and ready for the engraftment of donor bone marrow. Donor T and B cells present in the graft 
reconstitute adaptive immune capacity in the recipient16. Donor T cells have an additional 
beneficial effect against any remaining leukaemic or tumour cells within the host, a phenomenon 
known as graft versus leukaemia (GvL)16. However, donor T cells can also cause pathology 
involving the damage of host tissues called graft versus host disease (GvHD), which is primarily 
due to varying degrees of donor/host mismatch at both MHC and mHA. In effect, GvHD 
represents a mirror image of transplant rejection, in that it is the donor allogeneic T cells that 
recognise the recipient host cells bearing recipient MHC antigen as “foreign”.  
 
1.4  GVHD 
 
GVHD is the major complication of HSCT limiting the use of this therapy. It can be 
compared during the first 100 days after transplantation17 (acute GvHD) or later (Chronic 
GVHD). Acute GvHD18 predominantly affects the skin (81%), gastrointestinal tract (54%), and 
liver (50%). The severity of acute GVHD is classified on the basis of organ involvement and is 
graded as follows19: grade I (mild); II (moderate); III (severe); and IV (very severe). The 
development of acute GvHD depends principally on genetic differences between donor and host, 
donor’s sex, and the stem cell source replete with donor T cells. The incidence of acute GvHD in 
patients receiving fully-matched transplantation is around 40% but it increases greatly with 
recipients differing of one HLA antigen up to 60-80%20. Chronic GvHD is a major cause of 
morbidity and mortality in long-term survivors of allogeneic stem cell transplantation. There is a 
classic type without features of acute GvHD and an overlap syndrome with features of both, 
acute and chronic GvHD. The classic one is a de novo syndrome and the latter one evolves from 
an acute GVHD. The occurrence of chronic GvHD varies widely between 6-80% interesting 
different organ like the skin, eyes, mouth, gut, liver, lungs, joints and genitourinary system, 
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which results in organ failure and decreased survival.  According to the severity of organs 
involved, chronic GvHD is scored as mild, moderate or severe. 
The development of acute GvHD occurs in three sequential steps:  
1. activation of host APCs; 
2. activation, expansion and differentiation, and trafficking of donor T cells; 
3. targeted tissue destruction by cellular and inflammatory effectors. 
The inflammatory status plus the cytoreductive conditioning causes damage to patient’s tissues 
with the secretion of danger signals, including tumour necrosis factor-α (TNF-α) and 
interleukins-1 (IL-) and 6. Furthermore, expression of adhesion molecules, costimulatory 
molecules, and MHC antigens on host APCs is increased. All these factors together result in the 
activation of host APCs. Following the presentation of antigens to T cells, a strong cytokine 
response is initiated. These cytokines further promote antigen presentation and the recruitment  
of effector T cells and innate immune cells, which further augment the pro-inflammatory 
cytokine milieu. Finally, the effector T cells, natural killer (NK) cells, macrophages and pro-
inflammatory cytokines result in end-organ damage, which is clinically recognized as acute 
GvHD in the skin, lungs, gut and liver. The resulting tissue damage, if not treated, will further 
amplify the process to more severe stages of GvHD pathology, which are extremely difficult to 
control21 
The pathophysiology of chronic GVHD mainly depends on the polarization of CD4
+
 T cells into 
T helper 2 (TH2) cells, but there are six hallmarks that are unique to this syndrome as reviewed 
by Blazar et al21.  
The first feature is the thymus damage by the conditioning regimen or by prior occurrence of 
acute GvHD. This damage results in decreased negative selection of alloreactive CD4
+
 T cells 
(second). Third, there is immune deviation to a TH2-type cytokine response with the production 
of IL-4, 5 and 11. This response leads to the release of fibrogenic cytokines  principally 
transforming growth factor-β1 (TGFβ1). All is accompanied by macrophages activation and 
their production of platelet-derived growth factor (PDGF) and TGFβ1. These molecules induce 
the proliferation and activation of tissue fibroblasts. Low numbers of Treg cells are the fifth 
hallmark and finally there is B cell dysregulation which leads to the emergence of autoreactive B 
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cells and the production of auto-reactive antibodies. It has been suggested that autoreactive B 
cell activation may be due to the presence of high levels of B cell-activating factor (BAFF) in the 
lymphoid microenvironment. All these events contribute to an autoimmune-like systemic 
syndrome that is associated with fibro-proliferative changes.  
 
 
 
Figure 2  Pathogenesis of acute (top) and chronic (bottom) GVHD. From Blazar et al
21
.  
 
1.5  Immunosuppressive Drugs 
 
The transplant outcome depends on a delicate balance between immunosuppression and 
rejection, for this reason the use of appropriate doses of immunosuppressive drugs (ID) is 
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extremely important, especially in the first phases after the transplant. During the last 50 years 
the strategies utilized to prevent acute and graft rejection provide the use of different molecules 
acting principally to reduce the immune response against the transplanted organ. The first 
immunosuppressive drugs used were corticosteroids and azathioprine. Later on cyclosporine 
became the basic ID until a new calcineurin inhibitor, Tacrolimus, was introduced in the 90s. 
Tacrolimus was more powerful compared to Cyclosporine, but shared a similar spectrum of 
adverse effects. Tacrolimus is still today the drug of reference for renal transplantation. When 
used in combination with antiproliferative drugs such as mycophenolate mophetil the frequency 
of acute rejection episodes was below 20%. On the basis of their mechanisms of action ID are 
divided in 5 groups as explained in Table 1.   
 
 
Table 1 Mechanisms of action of immunosuppressive drugs. Derived from Immunosuppressive drugs: 
the first 50 years and a glance forward
22
. 
 
The calcineurine inhibitor Tacrolimus is a macrolide produced by the Streptomyces 
tsukubaensis fungus. Tacrolimus is now preferred to cyclosporine for its potency, essential to 
reduce the dose and consequentially the related side effects. It becomes biologically active only 
when complexed with the immunophilin FK binding protein 12 (FKBP-12), that is different from 
the immunophilin (cyclophilin) to which cyclosporine binds. The complex FKBP-12-tacrolimus 
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interferes with the transduction pathway of the intracellular calcium-dependent signal, which is a 
fundamental processes for the activation of T lymphocytes. The biological target of the complex 
is the calcium/calmodulin-dependent protein phosphatase, calcineurin, a fundamental molecule 
for the reactions necessary to the synthesis of various cytokines, including IL-223. The 
tacrolimus-FKBP-12 complex has a strong inhibitory dose-related effect on calcineurin 
phosphatase activity and consequently on IL-2 expression. T cells activation after the antigen 
encounter, consist in intracellular calcium release and subsequent activation of the 
calcium/calmodulin complex. This is essential to form the competent T-cell transcription factor 
NFAT. Upon activation, NFAT translocates to the nucleus where it associates with other 
transcription factors, such as members of the activator AP-1 family, and binds to DNA to 
promote the transcription of IL-2. Inhibition of calcineurin prevents its ability to activate NFAT, 
affecting the transcription of cytokines important in the immune response. In addition 
calcineurin is also involved in the activation of NF-κB. It indirectly induces the degradation of a 
compound known as IκB, which is bound to inactive NF-κB and acts as an inhibitory protein, 
preventing NF-κB association with its nuclear target genes. The blockade of calcineurin activity 
by Tacrolimus and cyclosporine affects the ability of NF-κB to exert its action on the genes of 
the immune system. Recently it was discovered  that tacrolimus and cyclosporine are also 
involved in the inhibition of the mitogen-activated protein kinase (MAPK) pathway. In particular 
they act on JNK and p38 activated through the MAPK signalling cascade by T cell and CD28 
co-stimulatory receptors24. The principal adverse effects associated with tacrolimus treatment are 
dose dependent and include nephrotoxicity, neurotoxicity, disturbances in glucose metabolism, 
gastrointestinal disturbance and hypertension. 
Mycophenolate mofetil (MMF) is an ester of mycophenolic acid (MPA) obtained from a 
Penicillum species acting through the inhibition of inosine monophosphate dehydrogenase, an 
enzyme involved in the synthesis of nucleotides, leading to B- and T-lymphocyte proliferation 
inhibition25. This is the rate-limiting enzyme in de novo synthesis of guanosine nucleotides. T- 
and B-lymphocytes are more dependent on this pathway than other cell types are. Moreover, 
MPA is a fivefold more potent inhibitor of the type II isoform of IMPDH, which is expressed in 
activated lymphocytes, than of the type I isoform of IMPDH, which is expressed in most cell 
types. Three other mechanisms may also contribute to the efficacy of MPA in preventing 
allograft rejection and other applications. First, MPA can induce apoptosis of activated T-
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lymphocytes, which may eliminate clones of cells responding to antigenic stimulation. Second, 
by depleting guanosine nucleotides, MPA suppresses glycosylation and the expression of some 
adhesion molecules, thereby decreasing the recruitment of lymphocytes and monocytes into sites 
of inflammation and graft rejection. Third, by depleting guanosine nucleotides MPA also 
depletes tetrahydrobiopterin, a co-factor for the inducible form of nitric oxide synthase (iNOS). 
MPA therefore suppresses the production by iNOS of NO, and consequent tissue damage 
mediated by peroxynitrite22. Most authors describe side-effects in about half of the patients 
treated with mycophenolate mofetil therapy. Specific MMF-related side effects are 
predominantly of a gastrointestinal nature, including diarrhoea, abdominal pain, decreased 
appetite with weight loss, nausea and vomiting. These appear dose related and reduce quickly 
when the drug is reduced. Other adverse reactions reported in literature are leukopenia (similar 
to azathioprine) and symptomless anaemia that is related to bone marrow toxicity. Infectious 
complications and malignancies have been observed, although long-term safety data must be 
awaited. CMV, HZV, HVI-1, Candida, and Aspergillus infections seem to be more common.  
Prednisone is a synthetic glucocorticoid obtained by dehydrogenation of cortisone. Its anti-
inflammatory, immunosuppressant and mineralcorticoid properties are only exhibited when is 
converted to prednisolone in the liver. Prednisolone is extensively bound to plasma proteins and 
is a potent therapeutic agent influencing the immune activation because of the ubiquitous 
expression of corticosteroid receptors. Corticosteroids inhibit antigen presentation, cytokine 
production, and proliferation of lymphocytes. It is believed that corticosteroids induce their 
effects on the cell through a glucocorticoid receptor in the cytoplasm. Corticosteroids induce 
lymphocytopenia as a result of redistribution of circulating lymphocytes into other lymphoid 
compartments (spleen and lymph nodes in primis). Another effect of corticosteroids is the 
complete inhibition of T-cell growth26 factor or IL-2. Therefore, T cells under the influence of 
corticosteroids lose their ability to proliferate and react to specific antigens. Moreover, it's 
responsible of a profound monocytopenia and inhibits inflammation by blocking responses to 
chemotactic factors and macrophage activation factor, phagocytosis and pyrogen production. 
The side effects of corticosteroids are not specific to lymphocytes and a number of serious 
adverse events are associated with the prolonged use. Complications of corticosteroid therapy 
involve any organ system in the body. Short and appropriate use does not have heavy 
complications however acute adverse effects include central nervous system effects, psychosis, 
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impaired glucose tolerance, and retention of salt and fluid. Long-term adverse effects are 
insidious in onset and tend to subside more slowly when therapy is discontinued.  
In summary, the use of ID has markedly reduced the incidence of acute rejection and early 
graft loss. However, the numerous adverse side effects observed, and failure to effectively 
prevent chronic allograft dysfunction of conventional immunesuppression boost the development 
of alternative strategies to avoid graft rejection. 
 
2.  Regulatory T cells 
 
2.1  Introduction 
  
The immune system has the function to destroy invading microorganisms and stop aberrant 
outgrowth of tumour cells. In the meantime, it has developed several mechanisms for preventing 
attack of healthy self tissues. Self-reactive T lymphocytes and B lymphocytes are eliminated 
during negative selection in the thymus and bone marrow, respectively. However, to block the 
immune cells escaping this first "barrier", the immune system have developed a series of 
peripheral mechanisms. For almost 40 years, immunologists have postulated the existence of 
suppressor T cells that police the immune system to avert unwanted immune responses. 
However, that phenomenology was cast into doubt as various labs presented unique, hard-to-
reproduce systems, each with complexities and idiosyncrasies that raised credibility issues. 
However, thanks to the identification of a constellation of cell surface, transcriptional and 
biochemical markers it was easy to find the unique mark of regulatory T cells27 (Treg). The 
realisation that Treg cells have a unique surface expression profile incorporating CD25, CD62L 
together with the identification of the Treg cell–specific transcription factor Foxp3, catapulted 
Treg from a rare CD4
+
 T cell subset to what many regard as 'master regulators' of immune 
homeostasis. After that a big scenario was opened and a myriad subpopulations of Treg cells 
where discovered, including the CD4
+
CD25
+
 Foxp3
+
 cells, including IL-10 secreting Tr1 cells28, 
TGF- secreting Th3 cells29, Qa-1 restricted CD8
+
 cells30, CD8
+
CD28- T cells31, CD8
+
CD122
+
 T 
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cells32, CD8
+
CD28- cells33. Some of these Treg cells, such as the CD4
+ 
CD25
+
Foxp3
+
 cells, 
originate in the thymus during ontogeny and are referred as natural Treg cells but they can also 
be induced from naive T cells in the periphery. 
 
2.2  Thimic origins of natural regulatory t cells  
  
Between the late 1960s and early 1980s was observed that thymectomy of mice on the 3rd 
day of life resulted in organ-specific autoimmune diseases, but that did not occur if neonatal 
mice were thymectomised on days 1 or 734. In addition, day 3 thymectomised mice could be 
prevented from developing autoimmunity if they received an infusion of thymocytes35. These 
experiments suggested that autoreactive T cells exit the thymus in the first three days of life 
followed a few days later by a population of suppressor cells that control the autoreactive cohort. 
Almost a decade later, Sakaguchi and colleagues identified a small population of CD4
+
 cells that 
expressed high levels of the IL-2 receptor -chain, CD25, whose depletion resulted in 
autoimmune diseases27 and whose transfer to neonatally day 3 thymectomised mice prevented 
disease36. The subsequent identification of humans and mice deficient in CD4
+
CD25hi cells 
which develop severe autoimmune diseases strongly suggests that these cells have a critical role 
in the maintenance of self-tolerance.  
In addition, adoptive transfer of Treg from donor animals lacking ovaries, testes, prostate or 
thyroid glands did not inhibit organ-specific autoimmune diseases caused by neonatal 
thymectomy37, suggesting that antigen specificity is imprinted on Treg during thymic education. 
As nTreg originate in the thymus, it is thought they initially undergo the same selective pressure 
and developmental checkpoints as conventional (αβ) T cells (Tconv). In order to understand how 
Treg develop in the thymus, it is important to understand the basis of T cell ontogeny. The two 
vital checkpoints that occur very close during thymocyte development are positive and negative 
selection. The former step involves the selection of thymocytes recognising self-MHC while the 
latter one involve negative selection of T cells with T cell receptors (TCR) at high avidity for 
class I and class II MHC molecules presenting self-antigens. Thus, duration and avidity of the 
TCR interaction with self-peptide-MHC complexes on antigen-presenting cells (APC) determine 
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thymocyte fate. Thymocytes that bind with high avidity undergo programmed cell death in an 
attempt to limit auto-reactivity in the periphery, while thymocytes with low avidity for self-
MHC:peptide are selected as Tconv. The interaction with either MHC class I or MHC class II
38 
allows for a series of signalling events important for developing respectively CD8
+
 or 
CD4
+
 single positive (SP) T cells. This engagement of TCR/co-receptor with MHC is vital in 
generating a T cell population that can distinguish self from non-self.  
Over 97% of all thymocytes that become DP cells will die by their failure to recognise, at 
any level, the presence of MHC and therefore will not receive survival signals through the 
TCR39. These cells are said "dead by neglect". The remaining thymocytes are thought to survive 
initially by the recognition of low-affinity peptides as described in the “kinetic signalling” 
model. In this model it is proposed that signal intensity allows for positive selection and then 
signal duration allows for CD4/CD8 lineage commitment. Subsequently, the recognition of self-
peptide with high affinity/avidity by the TCR will direct the thymocyte towards controlled 
apoptosis and deletion40. In the thymus, the αβ TCR is expressed on thymocytes entering the DP 
stage of development. The TCR transmits any intracellular signals from external stimulation by 
the association with the CD3 complex. Each of the four (ε,γ,δ,ζ) chains in the TCR-CD3 
complex contain immunotyrosine activation motifs (ITAMs) that can be phosphorylated by 
protein tyrosine kinases to recruit downstream signalling molecules. A relatively high number of 
ITAMs found within the CD3 complex is needed to ensure a critical threshold of signalling 
possibly through the recruitment and activation of certain downstream signalling molecules such 
as the tandem Src homology 2 (SH2) domain-containing ζ-chain-associated protein of 70 kDa41 
(ZAP-70). It has been shown that recruitment and activation of the ZAP-70 substrate, linker of 
activated T cells, is essential in the development of FOXP3
+
 T cells in the thymus and the 
periphery42. nTreg development takes place solely in the thymus but the complete mechanisms 
aren't fully understood. It is widely known that FOXP3 expression does not commence until day 
3 in neonates and it has been postulated that the thymic architecture is essential to provide a 
proper co-stimulatory signals for FOXP3 expression43. Many co-stimulatory signals have been 
implicated in the development and lineage commitment of nTreg including: CD28 ligation by 
CD80/CD86, IL2R, thymic stromal-derived lymphopoietin receptor (TSLPR), CD154, 
glucocorticoid-induced tumour necrosis factor receptor (GITR), and STAT5 
signaling44.  nTreg are resistant to apoptotic signals, mechanism in part due to the expression of 
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GITR but even anti- and pro-apoptotic molecules Bim and Bcl2.  For example, it was reported 
that Bim
−/−
 mice have an increase in total Treg while there is an increase in the frequency of 
FOXP3
+
 Treg in Bcl2 transgenic mice. Another co-stimulatory pathway necessary for 
nTreg development is the of CD28-CD80/CD86 interaction because mice KO for CD28 or 
CD80/86 have a marked reduction of FOXP3
+
Treg45.  IL-2 appears to have a significant role in 
development and maintenance of Treg in periphery and in thymus as well. IL-2Rβ-deficient mice 
have a loss of functional Treg46. In addition, when there is a lack of IL-2 or the IL-2R, there is a 
50% reduction in thymic Treg indicating that this one is only a part of several signals needed for 
Treg development44.
 
Exploiting these discoveries has been introduced a two-step model of 
nTreg development47. When developing thymocytes recognise a self-peptide they upregulate 
CD25 allowing for their rescue by IL-2- and STAT5-mediated signaling within the medulla and 
their progression into the Treg lineage. In addition to IL-2R signaling, ligation of TGFβR also 
appears to be involved in development and maintenance of nTreg. The role of TGFβ became 
clear when TGFβ receptor I KO-mice were used. In this model was found that numbers of 
CD4
+
CD25
+
FOXP3
+
 thymocytes were greatly reduced in young mice, between days 3 and 5 of 
age48. The reduction in CD4
+
CD25
+
FOXP3
+
 thymocytes is only temporary, and the numbers of 
thymic FOXP3
+
 Treg rapidly recover due to increased production of IL-2. Of note, 
CD4
+
CD25
+
FOXP3
+
 thymocytes were completely lost when mice lacking both TGFβRI and IL-
2 were generated. From this work it is apparent that TGFβ is an important upstream mediator of 
FOXP3 expression although other signals, including TCR signaling, are necessary. 
FOXP3 expression within the thymus was facilitated by the generation of FOXP3-GFP 
reporter mice. Using these experimental models it was clearly established that FOXP3 
expression is predominantly seen at the CD4 single positive stage of development. However, a 
small percentage of GFP
+
 cells were also seen in the double positive, CD8 single positive 
populations and at the immature double negative stage of thymocyte development. Using GFP as 
a marker for FOXP3 expression, it was determined that the majority of GFP
+
 cells are found 
within the medulla of the thymus. In addition, it has been shown that thymic stromal-derived 
lymphopoietin (TSLP) produced in the medullary region of the human thymus is critical for 
Treg development49 giving credence to the notion that nTreg development is medullary. 
However, thymic dendritic cells (tDCs) also produce TSLP. nTreg develop from the cortical 
region of the thymus as well, but require other co-stimulatory signals for lineage commitment 
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and survival. Explaining the T cells generation is important to focus the attention on the 
autoimmune regulator gene (Aire)50 essential for negative selection. Aire is expressed in thymic 
medullary epithelial cells (mTEC) allowing the expression of many peripheral-tissue antigens 
that would otherwise be absent during negative selection. It is possible that interactions with 
AIRE-expressing mTECs could also initiate FOXP3 expression within CD4 SP immature 
thymocytes51. However, AIRE expressing mTECs undergo rapid turnover, allowing for cross-
presentation of antigens by traveling tDCs. which then present AIRE antigens in the cortex and 
the develop of nTreg at the DP stage.  
These data indicate that initiation of FOXP3 expression within DP and SP thymocyte 
populations may be due to a combination, and possibly an accumulation, of signals mediated by 
the TCR, cytokine receptors and co-stimulatory molecules. From these observations a variation 
of the two-step model has been proposed52 where nTreg development begins with a population of 
pre-Treg generated by unknown mechanisms. After successful rearrangement of the TCR, pre-
Treg will recognise a diverse repertoire of self and foreign antigens but only progress to mature 
nTreg by the accumulation of TCR-dependent and independent signals including a pathway that 
allows for survival under negative conditions. In this model, TCR dependent and independent 
signals have variable levels of importance within any given developing nTreg.  
 
2.3  Regulatory T cell markers    
 
Although CD25 expression was the original defining feature of Treg, it is also expressed by 
antigen-experienced and recently activated conventional T cells. As a result, CD25 is of greatest 
sensitivity when used to identify Treg from naive T cell populations such as cord blood T cells 
or antigen-naive animals. As a result, in antigen-experienced mammals, only the top 2% of 
CD25 expressing CD4
+
 cells contain genuine Treg53. In the description of Treg therefore, a 
number of additional markers have been described as putative Treg-specifying, but none of 
which are wholly perfect on their own. Some however, identify subsets of Treg which may have 
slightly different functions.  
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 2.3.1   FOXP3  
 
The Scurfy mouse, an X-linked mutant strain, described in 1949, exhibits a series of 
autoimmune features including skin scaliness, diarrhoea and death in association with CD4
+
 T 
cell hyper-proliferation, multiorgan CD4
+
 cell infiltration and over-production of several 
inflammatory cytokines54. This fatal autoimmune lymphoproliferative syndrome was found to 
map to a gene locus on the X chromosome called Foxp3, which was described as a new member 
of the forkhead/winged-helix family of transcription factors55. The Foxp3 gene is highly 
conserved between species and a mutation in the human gene, FOXP3, was identified as the 
causative factor responsible for the human equivalent of Scurfy, the Immunodysregulation, 
Polyendocrinopathy and Enteropathy, X-linked syndrome (IPEX), also known as X-linked 
autoimmunity and allergic dysregulation syndrome56 (XLAAD). Both the mouse and human 
disease lack discrete circulating Treg, suggesting that this gene is essential for Treg development 
in mice and humans as well. Foxp3 knockout mice don't present circulating Treg; these animals 
develop a Scurfy-like syndrome reverted by the adoptive transfer of Treg from a Foxp3 replete 
animal57. Furthermore, ectopic or over-expression of Foxp3 in CD4
+
CD25
-
 mouse cells results in 
development of a Treg phenotype. In mice, Foxp3 expression is a good phenotypic marker of 
Treg; in humans, however, FOXP3 does not allow the unambiguous identification of Treg58 as 
FOXP3 requires several signals for its stable expression and a regulatory phenotype.  
A number of signalling pathways triggered by surface receptor-ligand interactions converge 
to synergistically transcribe the FOXP3 locus. For example, TCR cross-linking in human cells 
triggers well-characterised proximal signalling events, including phosphorylation of conserved 
immunoreceptor tyrosine-based activation motifs (ITAMs) in CD3 chains by members of the Src 
tyrosine kinase family. Phosphorylation of ITAMs on CD3 allows binding of zeta associated 
protein 70 (ZAP70) which permits the activation of transmembrane proteins such as Linker of 
Activated T cells (LAT). Phosphorylated LAT in turn interacts with a number of intermediate 
signalling proteins. These proximal events lead eventually to the binding of the transcription 
factors Nuclear Factor of Activated T cells (NFAT) and Activator Protein 1 (AP-1) to the 
FOXP3 promoter inducing its transcription. Proximal and distal signalling events are coupled 
together by Protein Kinase C (PKC) and Calcineurin  as murine knockouts of either PKC and 
Calcineurin have greatly diminished Treg numbers59. In  mouse, TCR ligation also results in an 
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increase in intracellular cAMP which leads to the downstream binding of the cAMP-Responsive 
Element Binding Protein (CREB) and Activating Transcription Factor (ATF) to a TCR-
responsive enhancer in the Foxp3 first intron43. In naive peripheral T cells, T activation also 
results in the propagation of an inhibitory signal to Foxp3 expression. This is mediated by the 
PI3K Protein Kinase B (AKT) and mammalian target of rapamycin (mTOR) pathway as 
inhibition of each of these leads to Foxp3 upregulation60. 
Even the CD28 co-stimulation can induce expression of Foxp3 in developing thymocytes in 
a cytokine-independent manner61. However, peripheral co-stimulation through CD28 impairs the 
conversion of naive T cells to the regulatory phenotype, suggesting that co-stimulation 
requirements for stable Foxp3 expression differ between nTreg and induced Treg (iTreg). This 
agrees with previous observations that the conversion of naive T cells to the regulatory lineage is 
enhanced in the presence of sub-optimal activation62. CD28 signalling has overlapping signalling 
pathways with those activated following TCR stimulation,  
Cytokine signalling is very important for Treg differentiation since mice with disrupted IL-2 
signalling pathways have no Treg57, however IL-2 is not the only one. IL-2 signal transduction is 
mediated by the well-characterised JAK-STAT (Janus Kinase-Signal Transducer and Activator 
of Transcription) pathway involving JAK1, JAK3 and STAT5. The JAK/STAT pathway is a 
receptor-coupled signal transduction mechanism linking cytokine-receptor interactions to gene 
expression. JAK proteins are present in association with the cytoplasmic tails of multimeric 
cytokine receptors and are activated upon receptor dimerisation. Once activated, STATs 
dimerise and translocate to the nucleus to regulate gene transcription by binding to specific 
promoter regions. In IL-2-signalling, phosphorylated STAT5 binds directly to an intronic region 
in the FOXP3 gene and induces transcription63. As expected, murine knockouts of both Jak3 and 
Stat5 have few or no circulating Foxp3
+
 cells64. TFG-β can induce FOXP3 through two separate 
but concurrent pathways. Both the transcription factors TGF- β inducible early gene 1 (TIEG1) 
and Mothers Against Decapentaplegic 3 (SMAD3) bind to promoter regions in the FOXP3 gene 
and enhance its expression65. There are additional factors which synergise with the TGF- β 
signalling pathway to promote transcription of the FOXP3 gene including retinoic acid and 
Notch-signalling66, while others, such as GATA3 and IRF1 (Interferon Regulatory Factor 1), 
inhibit this pathway of Treg differentiation67.  
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2.3.1.1   Regulation of the FOXP3 gene 
 
Regulation of the FOXP3 locus is critically controlled by epigenetic modifications which 
determine chromatin structure and alter the accessibility of the gene locus to transcription 
factors. These modifications include histone acetylation and methylation as well as methylation 
of CpG dinucleotide-rich regions within promoter sites. In FOXP3 locus it's possible to find 
three noteworthy non-coding regions which are susceptible to epigenetic modifications (Figure 
3). These are: the FOXP3 promoter, TGF-β sensor and Treg-cell-specific demethylation region 
(TSDR). CpG motifs in the FOXP3 promoter region are basally demethylated in resting Treg but 
partially methylated in conventional naive CD4
+
 T cells68. In addition, histones in this region are 
more acetylated in Treg than in naive T cells43. As a result, the FOXP3 promoter is more 
accessible for the binding of NFAT and AP1 in Treg than in conventional T cells. Murine 
experiments suggest that the Foxp3 promoter region in conventional T cells remains methylated 
following TCR activation, albeit at a lower level than at baseline68, and that demethylation 
requires activation in the presence of TGF-β43; these structural effects limit and promote access 
for induction of Foxp3 transcription respectively. The second, highly conserved region in the 
Foxp3 locus contains binding sites for NFAT and SMAD3 and is in an accessible state in nTreg 
and in naive T cells skewed to a Treg phenotype by TGF-β in the presence of anti-CD3 and anti-
CD28 stimulation65. For this reason the area is known as the TGF-β sensitive enhancer element. 
This area has no CpG motifs, therefore the sole epigenetic modification at this locus is through 
histone acetylation. At baseline level it is not accessible in naive, resting T cells, limiting 
availability of the Foxp3 gene for transcription. TGF-β induced SMAD3 binding to this region 
upregulates Foxp3 transcription at early time points after stimulation whereas the enhancer 
effects of NFAT on this region are of a slightly longer duration. A third, highly evolutionarily 
conserved, CpG dinucleotide-rich region has been identified in both mouse and human cells 
which is completely demethylated in Treg but methylated in conventional T cells69. This area 
contains a nTreg specific demethylated region and, in addition, acetylated histones70. it is 
characterized by 2 transcription factor binding sites, which in the demethylated state bind 
STAT5 and CREB/ATF respectively71; epigenetic modification at this section are unaffected by 
TGF-β signalling. The TSDR was initially described as having enhancer activity however to date 
it is well established that TSDR demethylation is critical for the stability of FOXP3 expression71. 
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The signals controlling methylation/demethylation at the TSDR are currently unknown but given 
the difference between iTreg and nTreg in FOXP3 stability, it is likely that demethylation at this 
locus is initiated in the thymus. 
 
 
Figure 3. Epigenetic control of the FOXP3 locus. Three distinct regions of the FOXP3 gene are 
susceptible to epigenetic modification. These are the FOXP3 promoter, TGF-β sensor and Treg-cell-specific 
demethylation region (TSDR). Accessibility of these loci to transcription factors in FOXP3
-
 Tresps (A), TGF--
induced FOXP3
+
 cells (B) and stable FOXP3
+
 Treg cells (C) are depicted. Adapted from Huehn et al
70
. 
 
2.3.2   Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and Glucorticoid-Induced TNF 
Receptor (GITR)  
 
CTLA-4 (CD152) is a receptor related to CD28 that displays approximately 30% homology 
with CD28 at the protein levels and binds the same ligands, B7-1 and B7-2, on APCs72. CTLA-4 
is not expressed in the naive and resting state but it is upregulated upon T-cell activation in a 
CD28-dependent manner. On the other hand it is constitutively expressed in Treg and represents 
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one of the hallmarks of this cell subset. CTLA-4 KO mice develop a lymphoproliferative disease 
characterized by massive T-cell activation and expansion that leads to multi-organ infiltration 
and causes the animal death within two-to-four weeks after birth Then It was showed using 
mAbs treatments blocking CTLA-4-B7 interactions73 that CTLA-4 is important for both the 
induction of anergy and the maintenance of T-cell unresponsiveness. To date is well established 
that CTLA-4 plays a critical role in the suppressive function of Treg even though compensatory 
mechanisms exist in CTLA-4-deficient mice allowing the generation of functional Treg that 
control immune responses through  alternative pathways. These compensatory mechanisms are 
not always sufficient to generate Treg populations capable of controlling effector T-cell function. 
Indeed, Schmidt et al74 recently reported that ovalbumin-specific CTLA-4-deficient Treg were 
unable to control disease in an adoptive transfer model of autoimmune diabetes into recipients 
expressing ovalbumin in pancreatic islets. It is unclear why CTLA-4-deficient Treg cells work in 
some settings and not others in vivo, but it could be due to the model used and/or the 
mechanisms of action required to control different disease. Moreover, it has recently been 
suggested that CTLA-4 could dampen the homeostasis of Treg by regulating their expansion 
since defective CTLA-4 signals following mAbs blockade or in CTLA-4-deficient cells led to 
amplified proliferation of Treg74. In this regard, it is intriguing that a 30–40% increase in the 
frequency of CD4
+
CD25
+
 Treg was observed in the blood of healthy individuals homozygous for 
a single nucleotide CTLA-4 polymorphism associated with decreased susceptibility to 
autoimmune disease75.  
First cloned in 1997 following treatment of a hybridoma T cell line with dexamethasone76, 
GITR is a member of the TNF receptor (TNFR) superfamily which is expressed on components 
of both the innate and adaptive immune systems, including NK and T cells77. Its natural ligand, 
GITRL, is a member of the TNF superfamily (TNFSF) and is expressed on endothelial cells and 
antigen presenting cells (especially macrophages, DC and B cells). GITR acts as a T cell co-
stimulatory molecule upon encounter with GITRL-expressing APC presenting cognate antigen, 
leading to enhanced T cell proliferation and cytokine production78, with the ability to substitute 
for CD28 co-stimulation to rescue T cells from CD3-induced apoptosis. At the beginning GITR 
was considered a perfect Treg marker cause of its high expression in Treg, abrogation of Treg 
suppression by GITR neutralisation79 and its induction upon Foxp3 transduction of CD4
+
CD25
-
 
cells. However the starting enthusiasm diminished after the observations that GITR can be 
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expressed and up-regulated in non-regulatory CD4
+
 cells upon activation and that GITRhi 
CD4
+
CD25
+
 cell lines are not suppressive79. This is supported by in vivo data cause Treg from 
GITR KO-mice still retain suppressive function78.   
 
2.3.3  IL-7 receptor α-chain (CD127)  
 
IL-7 is a member of a cytokine family which includes IL-2, IL-4, IL-9, IL-15 and IL-21 
whose receptor complex utilises a common chain (CD132) in association with a cytokine-
specific high affinity chain, for example CD25 for the IL-2 receptor and CD127 for the IL-7 
receptor. IL-7 is essential for T cell development since IL-7 knockout mice exhibit severe T cell 
deficiency80. CD127 is a naive T cells marker, lost from the cell surface upon T cell activation 
and then re-expressed by memory cells81. Both naive CD4
+
  CD8
+
 cells exiting from the thymus 
have low expressions of receptors for IL-2 and IL-5 but they are critically dependent on the 
presence of IL-7 for survival82. Recent evidence has also implicated CD127 as a possible 
biomarker of Treg as the combination of CD4 and CD25 together with low expression of CD127 
identifies a group of peripheral blood T cells which are highly suppressive in functional assays 
and the highest expressers of FOXP383. Indeed, CD127 is a direct FOXP3 target, which may 
reflect the mechanism of the inverse correlation between levels of CD127 and FOXP3. The 
utility and drawbacks of CD127 as a unique Treg marker have yet to be fully evaluated; 
nevertheless, the combination of CD4
+
CD25
+
CD127lo surface markers appear promising as 
identifiers of Treg populations. For this reason CD127 is very important because it could be used 
in clinical trials to isolate a high pure Treg population .  
 
2.3.4   Galectins 
 
Galectin are lectins which bind β-galactoside. Using transcriptomic and proteomic assays to 
identify Treg-markers, two separate groups described expression of members of the galectin 
family on Treg cells .Galectin-1 is expressed by Treg cells at baseline and upon TCR 
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engagement in both mice and humans84. Galectin-10 was also identified as constitutively 
expressed by Treg cells85. Antibodies blocking this molecule also abrogated Treg suppression in 
vitro. Interestingly, Treg cells from galectin-1 knockout animals are numerically normal but 
functionally less suppressive than their wild-type counterparts. However, expression of galectin-
10 is restricted to intracellular compartments, which renders galectin-10 unsuitable to enrich 
viable nTreg populations. 
 
2.3.5  Other regulatory T cell markers 
 
Others Treg-associated surface markers have also been described in literature but they 
generally identify sub-population of Treg. One of this is HLA-DR expressed on a subpopulation 
of Treg cells including approximately 20-30% of human CD4
+
CD25
hi
 T cells53. Opposite to the 
HLA-DR negative counterpart HLA-DR
+
 CD4
+
CD25
hi
 T cells suppress via an obligate contact-
dependent mechanism. However, these Treg populations suppress both proliferation and 
cytokine production by target T cells. The inducible T cell co-stimulator ICOS (CD278) has 
been described on a subpopulation of both thymic and peripheral FOXP3
+
 cells86. ICOS is a 
member of the CD28 and CTLA-4 family of co-stimulatory molecules and it is expressed on the 
surface of activated T cells where it forms homodimers upon engagement of its ligand, (ICOSL, 
CD275) playing an import role in cell-cell signalling and immune responses. In murine system, 
ICOS was found to be an important marker of induced CD4
+
 Treg87 and plays indispensable 
roles in induction and maintenance of immune tolerance besides its function in regulating the 
differentiation of effector T cells. Murine CD4
+
ICOS
+
 Treg demonstrated better survival, 
proliferative, and even suppressive abilities than their ICOS
-
 analogues. The expression of ICOS 
was recently found to promote the generation, drive the activation and improve the function of 
human CD4
+
 Treg as well88. In clinic, ICOS
+
CD4
+
 Treg has been identified in type I 
autoimmune pancreatitis patients and found to help ameliorate the disease severity. The 
expression of ICOS on human Treg cells seems to direct these cells toward different cytokine 
profiles as CD4
+
CD25
+
ICOS
+ 
T cells that produce both IL-10 and TGF-β, whereas 
CD4
+
CD25
+
ICOS
 -
 T cells produce only TGF-β86. 
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2.4   Regulatory T cells and chemokine receptor 
 
As members of the T cells subset, Treg traffic to different parts of the body at different stages 
of development, maturation, and activation. This trafficking is mediated by cytokines, integrins, 
chemokines, and matching receptors. Chemokines are divided into the CXC group and the CC 
group, so named for the patterns of cystine residues in their binding domains. They are 
characterised by a basal affinity for a wide range of chemokine receptors, but only few of them  
display high affinity. Mailloux et al89 reviewed the stimuli that selectively recruit Treg over 
conventional effector populations  
 
Table 1 Chemokine receptor expressed by Treg. Derived from Regulatory T-cell Trafficking: 
From Thymic Development to Tumor-Induced Immune Suppression
89
 
33 
 
nTreg emigrate from the thymus into the periphery and secondary lymph tissues so, it is 
evident that they express different chemokine receptor on the basis on their activation status. In 
contrast to nTreg, inducible Treg emerge from conventional effector populations in response to 
stimuli associated with a suppressive or otherwise altered microenvironment. These cells also 
traffic in response to network of migratory signals, although in many cases the specific factors 
and receptors involved may be distinct from those for nTreg90. Treg development may be 
accomplished both directly and indirectly by epithelial cells within the Hassal's corpuscles (HC) 
in the thymus. Epithelial-derived factors such as the EBI1-ligand chemokine (CCL19) and the 
macrophage-derived chemokine (CCL22) are highly expressed in distinct subsets of the medulla 
such as the HC, where high levels of Treg congregate. Moreover, HC epithelial cells produce a 
cytokine milieu that is distinct from thymic stroma, which greatly influences other resident cell 
populations, in fact, DC activated in this area produce Thymus and activation-regulated 
chemokine (TARC) and MDC91. Both have high affinity for CCR4 and can induce selective 
chemoattraction of Treg through this receptor. If CCR4 is expressed on developing thymic Treg, 
its expression is not as prominent as CCR8 which is primarily associated with the chemokine 
CCL1/I-309. Another chemokine of interest in thymic Treg trafficking is SDF-1 (stromal-
derived factor-1) and its cognate receptor CXCR4. However, CXCR4 expression is not limited 
to thymic Treg since SDF-1 may recruit early thymocytes to the HC, for this reason is not 
considered selective for Treg. However, more comprehensive Treg-migration studies would be 
needed to better  understand Treg-trafficking signals within the thymus. Polyclonal and highly 
reactive to self-peptides, naive nTreg emigrate from the thymus and traffic to secondary 
lymphoid tissues, where they can exert suppressive effects. Chemotaxis studies demonstrate that 
naive nTreg migrate toward CCL19 in a CCR7-dependent manner, and that this migration results 
in Treg homing to the T-cell zones in lymph nodes. Essential for Treg role is the CD62L. Animal 
model using antibody blocking CD62L showed a reduced Treg numbers in draining lymph nodes 
but not in the spleen92. Although not essential for the suppressive ability CD62L is essential to 
direct Treg in lymph-node where their localisation is critical for the regulation of immune 
homeostasis. Activated Treg in the periphery trafficked to draining lymph nodes in a CCR2- and 
CCR5-dependent manner. However CCR2 and CCR5 involvement was not studied in 
conventional T-cell migration. Upon activation, nTreg lose expression of CCR7 gaining the 
expression of CXCR5. At this level they are chemotactically responsive to CXCL1393 essential 
to recruit B cells to the B-cell zones in lymph nodes94.  Here Treg are unique among T cells since 
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they localise in B-cell follicles and can act inhibiting B-cell activation, expansion, and antibody 
production. Once mature, Treg migrate and take up residence in peripheral tissues.  
The majority of studies regarding Treg migration to the periphery are in the context of 
inflammation, infection, cancer and induction of transplant tolerance. However not a lot is  
known about the adoptively transferred Treg traffic, or how this subset could be manipulated to 
maximise their therapeutic potential in the transplant setting because Treg in the wrong place 
may provide undesirable immune response to the graft, but it may also prevent beneficial 
immune responses to pathogens. Interference of the CCR7 and CD62L was shown to abrogate 
tolerogenic function in a mouse cardiac allograft model in which tolerance was induced by 
donor-specific infusion and anti-CD40 ligand95, and in an islet allograft model with adoptive 
transfer of Treg. Animal studies96 used adoptive Treg transfer in a mouse islet allotransplant 
model, to show that Treg first migrate into the target tissue, where they become activated, and 
then traffic to the draining lymph node. The first step is dependent on Treg expression of P-
selectin and E-selectin ligands as well as CCR2, CCR4, and CCR5, whereas subsequent 
migration to lymph nodes requires CCR2, CCR5, and CCR7. Treg trafficking cues in 
allotransplant tolerance models may vary from model to model in fact a study, using a rat model 
showed that in kidney allotransplant model tolerant recipients demonstrated a CCL5 gradient 
between graft and circulation and that (endogenous) Treg expressing the CCL5-receptor CCR5 
were markedly more numerous in tolerated grafts97. In contrast, using the same rat strain 
combination, tolerance to cardiac allotransplant appeared not to involve CCL5-dependent Treg 
recruitment to the graft. Others reports focus their attention on CCR4 and its ligand. Muller et 
al. reported that immobilisation of CCL17, CCR4 ligand, on graft endothelium, was able to 
enhance recruitment of host Treg to pig islet xenografts98. An alternate approach to over-
expressing a defined chemokine in the graft is to select subpopulations of Treg expressing 
subsets of chemokine receptors that will control the trafficking of adoptively transferred cells to 
specific sites of inflammation. For example, Treg that express the Th1 associated transcription 
factor TBX21, express CXCR3 and traffic to sites of Th1-mediated inflammation to suppress 
Th1 cells99. Similarly, Treg have been shown to ‘imitate’ Th2 or Th17 cells in order to suppress 
their responses100,101. The pertinence of this concept has recently been demonstrated in humans, 
in that CXCR3-expressing Treg were shown to be more potent than CXCR3
-
 Treg in suppressing 
IFN-γ production in mixed lymphocyte reactions. These data suggest that if the major rejection-
35 
 
driving Th-cell lineage and its chemokine receptor profile are known, then an appropriate 
subpopulation of Treg might be selected on the basis of the trafficking receptors they express.  
 
2.5    How regulatory T cells Work 
 
Treg are involved in the control of immune tolerance and homeostasis for this reason they 
have developed several mechanisms to exert their suppressive function on different cell subsets 
like CD4
+
 (Th1, Th2 and Th17) CD8
+
 T cells, macrophages, dendritic cells (DCs) natural killer 
(NK), NKT cells and B cells. In order to suppress, Treg need to be activated via their TCR but 
after that the suppressive function is completely antigen non-specific. To date the discussion 
about Treg-suppressive mechanisms is still opened cause of the different evidences concerning 
contrasting results obtained from in vivo and in vitro experiments. From a functional perspective 
the various potential suppressive mechanisms could be divided in four "modes of action": 
(Figure 4)102.  
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Figure. 4  Mechanisms used by Treg cells. Here are depicted the main mechanisms used by 
Tregs that could be divided in 4 groups: a) Suppression by inhibitory cytokines, b) suppression 
by cytolysis, c) suppression by metabolic disruption and d) suppression by targeting DC. From 
"How regulatory T cells works" 
 
2.5.1   Suppression by inhibitory cytokines.  
 
Immunosuppressive cytokines, IL-10 and TGF-β, were considered essential for Treg 
function; however to date,  the role of these cytokines in Treg-mediated suppression is still 
incompletely understood. In fact there are contrasting results from in vivo and in vitro 
experiment; neutralization of either IL-10 or TGF-β does not abrogate in vitro Treg suppression 
but, in contrast, IL-10 and TGF-β contribute, at least in part, to the in vivo suppression of IBD 
induced in mice by Treg depletion103. Moreover it should be considered that cytokine secretion 
seems to be a mechanism involving principally iTreg suppression activity. In fact Tr1 cells 
modulate immune responses mainly through the secretion of IL-10 and TGF-β104 inhibiting T-
cell responses by suppressing IL-2 and IFN-γ105 and by preventing T-cell proliferation106. IL-10, 
locally released by activated Tr1 cells, also acts on APCs, by down modulating co-stimulatory 
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molecules and production of pro-inflammatory cytokines107  and on B cells by promoting isotype 
switching108. Some reports shown that in allergy and asthma models both nTreg and iTreg are 
involved in disease-control using a mechanism involving IL-10 and TGFβ. Two recent studies 
also delineate that IL-10R signaling is needed in Treg as well as in Th17 cells in order to 
suppress colonic Th17 responses109. In conclusion, the discrepancies found when comparing 
different studies indicate that the production of IL-10 by Treg and the role of IL-10 in Treg-
mediated suppression is most likely dependent on the microenvironment in which the Treg cells 
are activated but also on the experimental model. Transforming growth factor-β (TGFβ) is an 
important regulator of T cell tolerance through the induction of Treg cells in the periphery but  
now a study from Ouyang, et al has shown that it also functions in the thymus where it protects 
deletion-thymocytes and promotes natural TReg cell development and homeostasis. When we 
look at the role of TGF-β in Treg-mediated suppression we can find different results. Several 
studies, both in mice and humans, have used neutralising antibody against TGF-β or KO mice 
shown that the suppressive capacity is independent of TGF-β because the immnesuppresive 
capacity wasn't reversed110. Interestingly, the surface bound TGF-β has an essential role in the 
suppression, possibly by acting directly on the responder T cells or DCs. Nakamura K and 
colleagues111 demonstrated that after activation (by plate-bound anti-CD3 and soluble anti-
CD28) CD4
+
CD25
+
 T cells produce and express on their membrane high levels of transforming 
growth factor TGF-β1. This, plus their evidence that a soluble factors doesn't mediate 
suppression, suggests that CD4
+
CD25
+
 T cells exert immunosuppression by a cell–cell 
interaction involving cell surface TGF-β1.  
IL-35 is a recently discovered cytokine, this is the youngest member of the IL-12 family the 
only one with a purely immunosuppressive role. IL-35 was identified in the mid-2000s by Dario 
Vignali and colleagues, and was soon considered a potent mediator of suppression secreted 
principally by Treg. IL-35 is a heterodimer composed of the p35 and Ebi3 subunits, over-
expressed by Treg and not effector cells. Several works show how this cytokine is essential for 
the maximal suppresive activity of murine Treg since deficiency in one of the two IL-35 chains 
had reduced suppressive ability in vitro and in vivo in an IBD model. The difference between 
this and the other immunosuppresive cytokine concern the ability to differentiate naïve human T 
cells in a new population called iTR35 that mediated suppression via IL-35 but did not require 
IL-10, TGF-β, or Foxp3112. Although naïve human Treg did not express high amounts of IL-35, 
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long-term activation of human Treg led to upregulation of the IL-35 subunits starting at 3 days of 
activation113. These long-term activated Treg exerted contact-independent in vitro suppression in 
an IL-35-dependent manner and also induced iTR35 cells. Thus, IL-35 has been proposed as one 
of the infectious tolerance key players. 
 
2.5.2    Suppression by cytolysis. 
 
This process is mediated principally through the secretion of granzymes, a family of serine 
proteases inducing apoptosis and playing a significant role in the immune defense against 
viruses, tumours and intracellular bacteria. These are stored in granules that fuse with the plasma 
membrane of the target cells and release their content which also include perforin. This forms 
transmembrane pores on the plasma membrane that allows the diffusion of granzyme into the 
cytosol where they initiate caspase-dependent and independent apoptotic pathways, which 
rapidly lead to target cells death. These, were considered for a long time a specific products of 
natural killers cells and CD8
+
 cytotoxic T lymphocyte (CTLs) till the discovered in 2005 that 
Treg from grazyme-B-deficent mouse had a reduced suppressive activity in vitro cause a reduced 
apoptosis granzyme-B dependent114.  Later this data were confirmed by others studies showing 
the importance of granzyme-B and perforine secreted by activated Treg in killing B-cells and 
suppressing the ability of NK and CTLs to kill tumour cells.  
Although granzyme and perforin are considered the main molecules involved in Treg-
induced apoptosis others mediators are found to be involved in this mechanism for instance 
tumour-necrosis-factor-related apoptosis-inducing ligand–death receptor 5, galectin-1 and 10.  
 
2.5.3    Suppression by metabolic disruption  
 
To date is well established that IL-2 is essential for  T-cell activation, proliferation, and 
death115. In contrast to conventional T-cells,  Treg highly express the IL-2R  α-chain (CD25), β-
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chain (CD122) and γ-chain (CD132) and have STAT5 phosphorylation in the steady-state. For 
these reasons they are extremely dependent of IL-2 signalling, indeed KO-animals for IL-2, 
CD25, or CD122 present severe autoimmunity57. Since Treg constitutively express CD25, they 
can sense and capture IL-2 as soon as it is produced, so the presence of Treg could reduce IL-2 
availability and limit T responses. Indeed, the presence of Treg leads to substantial competition 
for IL-2, resulting in impaired proliferation of T cells in vitro and in vivo
116,117. In addition Treg 
can control IL-2 production acting in the same time on T cells and dendritic cells (DCs).  DCs 
activation is blocked by the high CTLA-4 Treg levels as explained below. Importantly, the 
amount of CTLA-4 expressed on Treg is again regulated by IL-2 signals. So it's safe to say that 
Treg control the level of co-stimulation through CD80/CD86 surface expression not only during 
steady-state118, but, importantly, also during highly inflammatory processes. 
The occurrence of pathological events, such as inflammation, promotes a massive 
accumulation of extracellular ATP, which is consider a Key danger signal triggering pro-
inflammatory responses.  After activation by TCR, Treg upregulate CD39 which metabolize 
ATP in AMP, later this is degraded in adenosine by CD73. Treg-derived adenosine, activates 
Adenosine 2a (A2A) receptors expressed on T effector cells, which undergo reduced immune 
activity. In addition, adenosine generation triggers a self-reinforcing loop of Treg function 
because the stimulation of A2A receptors, expressed on these cells, elicits their expansion and 
increases their immunoregulatory activity. Treg cells can also transfer the potent second 
messenger cyclic-AMP to T-effectors via gap-junction reducing their proliferation, 
differentiation and IL-2 synthesis.  
 
2.5.4  Suppression by modulation of dendritic-cell maturation or function  
 
Treg cells, both in vitro and in vivo, not only act on T cells function but even on their 
differentiation and activation modulating the antigen presenting cells and consequently T 
effectors indirectly. Treg cells are the only T-subpopulation that constitutively expresses CTLA-
4; this molecule has like target CD80 and CD86, molecules  expressed by DCs and important for 
the co-stimulatory pathway. To date is well established that CTLA-4 interaction with CD80 and 
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CD86 blocks their increasing expression post DC-activation or even downregulates their 
expression induced by antigen-specific effector cells119. In fact CTLA-4-deficient Treg from 
mice aren't able to prevent CD80/CD86 expression like the wild-type counterpart120 while the 
opposite results is obtained using CTLA4-specific blocking antibody. In this way Treg cells 
disrupt the CD28-pathway acting on the interaction between T and DC cells. One mechanism 
that may mediate the down-regulation of CD80 and CD86 expression is trogocytosis, a process 
in which lymphocytes extract surface molecules through the immunological synapse from the 
APC to which they are conjugated. Interestingly, CTLA-4 deficiency doesn't alter the 
development or homeostasis of Treg cells or render them pathogenic but only invalidate their 
functional activity. 
This one is not the only mechanism used by Treg to modulate DCs. Importantly, it was also 
shown that Treg could modulate the indolamine 2,3 dioxygenase (IDO) a potent 
immunosuppressive molecule involved in the tryptophan catabolism. IDO activation leads to 
tryptophan deprivation and the accumulation of kynurenine metabolites. The consequences of 
IDO activity include restriction of antimicrobial growth and multiple immunoregulatory effects 
on T cells like  inhibition of T cell proliferation, conversion of naïve T cells in Treg and 
inhibition of the T helper type 17 (Th17) lineage. IDO induction was found to depend on high 
expression of CTLA-4 on the Treg cells121. 
Recent results have furthermore focused the attention on lymphocyte-activation gene 3 
(LAG-3 or CD223). This is a  CD4 homolog that binds MHC class II molecules with very high 
affinity. Binding of LAG-3 to MHC class II molecules expressed by immature DCs induces an 
ITAM-mediated inhibitory signal which involves FcγRγ and extracellular-signal-regulated 
kinase (ERK)-mediated recruitment of SRC-homology-2-domain-containing protein tyrosine 
phosphatase 1 (SHP1) that suppresses DC maturation and immunostimulatory capacity122.  
Fibrinogen-like protein 2 (FGL2) is a protein  secreted by T cells, especially regulatory T 
cells, exerting an immunoregulatory property. Recombinant FGL2 inhibits T cell proliferation in 
response to anti-CD3 and anti-CD28 and alloantigen stimulation. To support this, Treg 
from Fgl2
−/−
 mice are less suppressive than the WT and a polyclonal anti-FGL2 completely 
blocked the suppressive activity of Treg cells in a dose-dependent manner.  
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Neuropilin (Nrp-1) has been proposed to play a role in the interaction of Treg cells with DCs. 
Nrp-1 is preferentially expressed on Treg cells and can be induced by Foxp3 expression123. Nrp-1 
promotes long interactions between Treg cells and immature DCs reducing the DCs avaibility. 
All these mechanisms could be used by Treg but several questions still remain. Do these 
mechanisms operate synergistically or concurrently? And are they site dependent?  
A recent review from Yamaguchi et al124. has introduced the hypothesis that Treg can act 
differently on the basis of the immune status. During the physiological and non-inflammatory 
state Treg act to sustain natural self-tolerance reducing/eliminating activation signal from 
responder T cells while, during the inflammatory condition Treg mediate inactivation and killing 
of T responder cells and APC. So all the mechanisms involved in the CD28 pathway inhibition 
like CTLA-4-dependent down regulation of CD80/CD86 or IL-2 absorption and CD39/CD73-
dependent degradation of ATP are involved to maintain the steady-state condition, and for Treg 
survival and function. However whit an activated immune system the previous mechanisms are 
abrogated by a big presence of co-stimuli; in this phase Treg start to produce immuno-
suppressive molecules like IL-10, TGF-β, IL-35, granzyme, perforin and cAMP to directly and 
potently suppress the activation and expansion of responder T cells. Thus, the two modes or 
phases of Treg-mediated suppression mechanisms are differentially utilised in non-inflammatory 
and inflammatory conditions. It needs to be determined how these two modes of suppression 
operate in other strong immune responses such as transplantation of allografts. 
 
2.6   Induced regulatory T cells 
 
As discussed in the previous section, it is now clear that CD4
+
CD25
+
 Treg can be derived 
from two sources, namely those developing within the thymus and those generated in the 
periphery. Periphery Treg (iTreg) derive from the conversion of CD4
+
CD25
-
 T cells under 
specific stimuli including suboptimal dendritic cell activation, sub-immunogenic doses of 
agonist peptide, mucosal administration of peptide and presence of appropriate cytokines, 
notably TGF-β and IL-2. There are at present no clear phenotypic markers nor functional 
differences to distinguish nTreg from iTreg but the epigenetic differences between them could be 
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used only for their characterisation and not for their isolation. The mechanism(s) by which Treg 
are generated in the periphery are unknown. However, there are indications that, in the same 
manner as with Th1/Th2 cell polarisation, the antigenic stimulus may determine the commitment 
to a Treg phenotype125. Amongst the induced Treg one of the most studied population cause of its 
controversial, is the T helper3 (Th3) subset. This subset was described as an unusual Th2 like 
regulatory subset secreting TGF-β derived from orally tolerized animals induced by mucosal 
stimulation with antigen. It has been shown that Th3-mediated suppression is essential for the 
maintenance of oral tolerance, mechanism described as mediated by TGF-β secreted in response 
to CTLA4 ligation. Moreover the CTL4 signalling results important for the expression of the 
gut-homing receptor Lymphocyte Peyer patch adhesion molecule (LPAM) or alpha(4)beta(7) 
integrin. Th3 cells could be induced through cognate stimulation of pluripotent naïve CD4
+
 T 
cells by APC together with CD86 co-stimulation, particularly in the presence of TGF-β and IL-
429. However in the gut other co-stimulatory signals are involved. The presence of anti-IL-12 or 
IL-10 may enhance the expansion of Th3 cells by decreasing Th1-type cells, which can inhibit 
Th3 expansion126. However since Th3-cell function is dependent on TGF-β, and other described 
regulatory T cells may also function through on TGF-β, there may be a common pathway that 
leads to a regulatory cell that is TGF-β dependent.  
Tr1 cells are another T subset with regulatory function. They were firstly described in severe 
combined immunodeficient (SCID) patients who had developed long-term tolerance to stem cell 
allografts, suggesting that these cells might naturally regulate immune responses in humans127. 
IL-10 and Rapamycin Administration in vivo was also shown to induce Tr1 cells mediating 
tolerance in type 1 diabetic mice after pancreatic islet transplantation128. In humans, Tr1 are 
involved in inducing transplantation tolerance, as PBMC from patients who underwent islet 
transplant and became insulin independent produced significantly higher IL-10 when compared 
with transplant subjects that continued to be insulin-dependent129. Induction of Tr1 cells was also 
described in patients who spontaneously developed tolerance to kidney or liver allografts130. 
Taken together, these data indicate that IL-10-producing Tr1 cells can be induced under different 
states of transplantation tolerance and may be involved in inducing tolerance to allotransplants. 
Moreover, Tr1 cells have the advantage to be inducible ex vivo and therefore cells of the desired 
antigen specificity can be more easily generated. The big issue of this subset is the purity cause 
they lack of specific cell-surface markers. In fact, even a T-cell line highly enriched for Tr1 can 
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be contaminated with non-regulatory T cells and this might represent a significant caveat. 
Furthermore, it is unclear whether the phenotype of Tr1 cells generated in vitro is stable once 
they are transferred in vivo in humans. Importantly, Tr1 cells produce the immunosuppressive 
cytokine IL-10 only after activation with their specific antigen, but once activated, they can 
mediate some level of  bystander suppression.  
Maynard et al. have suggested another mechanism in which Tr1 may play a major role. This 
concern the maintaining of immune homeostasis to the intestinal microbiota131, which is 
consistent with the finding that loss of IL-10 results in the development spontaneous 
enterocolitis in IL-10 deficient mice. To date it is well established that Tr1 cells may play a 
crucial role in suppressing autoimmunity, not only in experimental autoimmune disease models, 
but also in many human autoimmune diseases by suppressing tissue inflammation and 
maintaining self-tolerance.  
Collison et al112 recently demonstrated that natural Treg cells, but not resting or activated 
Tconv cells, express and secrete IL-35. This is a member of the interleukin-12 (IL- 12) cytokine 
family and is an inhibitory, heterodimeric cytokine having an α chain (a p35 subunit of IL- 12a) 
and a β chain (an Epstein Barr virus induced gene 3 subunit). Ectopic expression of IL-35 
conferred regulatory activity on naϊve T cells and recombinant IL-35 suppressed T cell 
proliferation. IL-35 selectively acts on different T-cell subset populations and is believed to 
mediate natural Treg cells' suppressive activity and thereby assist Treg cells in immune system 
homeostasis and tolerance to self-antigens. To date it is possible to culture in vivo or ex vivo an 
isolated population of T naive cells with an effective amount of exogenous IL-35 until the cells 
convert to display the regulatory phenotype. The cells can also be cultured with an effective 
amount of a T cell activating agent, such as an agent that activates a TCR. These cells can 
suppress T cells proliferation in vitro and act efficiently in different mouse models of Foxp3−/− 
mice, multiple sclerosis and immune bowel disease112. 
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3.   Regulatory T cells and Cell therapy 
 
3.1  Rapamycin 
 
Rapamycin is a macrolide identified in the early 1970s as a potent antifungal metabolite 
produced by Streptomyces hygroscopicus. This was found to inhibit cell proliferation and to have 
potent immunosuppressive activity. For this reason, rapamycin is currently used for the 
prevention of kidney transplant rejection132 but even for the prophylaxis of graft 
rejection and GVHD. It acts on the Mammalian target of rapamycin (mTOR) a protein kinase 
that controls cell growth, proliferation, ribosomal biogenesis, vesicular trafficking, autophagy, 
cytoskeletal organization and cell size. mTOR is an atypical kinase containing a carboxy-
terminal serine/threonine protein kinase domain a FRAP–ATM–TTRAP (FAT) domain and a C-
terminal FAT (FATC) domain that might have a role in its structure and stability. Mammalian 
LST8 associates with the kinase domain of mTOR and is thought to facilitate mTOR signalling, 
but its precise role has yet to be defined. mTOR can form two distinct complexes; mTOR 
complex 1 (mTORC1) consisting in mTOR, LST8 and the regulatory associated protein of 
mTOR (RAPTOR) and mTORC2 formed by LST8 and rapamycin-insensitive companion of 
mTOR (RICTOR) and possibly MAPKAP1 (mitogen-activated protein kinase-associated protein 
1). Rapamycin binding the immunophilin FK506-binding protein 1A (FKBP12) is able to block 
the in vitro and in vivo activity of the complex, potentially by disrupting the RAPTOR-mTOR 
interaction. This activity isn't exerted on mTOR2 even if recent data indicate that prolonged 
exposure to higher doses leads to inhibition of mTORC2 signalling as well133. 
As mTOR can acts on different cell pathways, I will focus my attention only on its 
immunological activity (Figure 5). The mTORC1 complex is a regulator of cell growth and other 
processes downstream of PI3K–AKT, WNT–GSK3 (glycogen synthase kinase 3) and AMP-
activated protein kinase (AMPK) signalling. To date is clear how the dimer formed by tuberous 
sclerosis complex 1 (TSC1) and TSC2 act as upstream inhibitor of mTORC1. In the meantime, 
factors activating PI3K and subsequently AKT inhibit TSC2, by phosphorylating it, thereby 
negating the inhibitory effect of TSC2 on mTORC1. Others pathway can regulate negatively 
TSC1–TSC2 complex like for example RAS–MAPK (mitogen-activated protein kinase) 
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pathway. The inhibitory activity of the TSC1–TSC2 complex is mediated by inhibiting Rheb 
(RAS homologue enriched in brain), a RAS-like GTPase and a positive regulator of mTORC1. 
When mTORC1 inhibition is removed, it acts phosporylating S6 kinase 1 (S6K1) and the 
eukaryotic initiation factor EIF4EBP1 (eukaryotic translation initiation factor (EIF4E)-binding 
protein 1). This promotes mRNA translation and cell growth by enhancing the biosynthesis of 
the translational apparatus in the cell134. As rapamycin is a selective mTORC1 blocker we have a 
good knowledge about its signalling pathway, nevertheless this is not the same for mTORC2 
because of the lack of an mTORC2-specific inhibitor. Only in the last few years, using siRNA 
specific for RICTOR, it has became apparent that mTORC2 is important in mammalian 
development and several cellular processes like cytosketelon modulation135. 
 
 
Figure 5. mTor pathway in immune cells. mTORC1 and mTORC2 signals are influenced 
by growth factors cytokines, co-stimulatory molecules and antigen receptors, WNT proteins, 
cellular energy levels, as well as hypoxia, cellular stress and DNA damage. Derived from 
"Immunoregolatory function of mTor"136 
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The mTOR pathway is essential for the activation of different mechanisms in the immune 
cells. In fact, the mTOR inhibition on DCs maturation and differentiation is well-documented 
both in vitro and in vivo. Monocyte-derived DCs are not able to up-regulate CD86 when 
cultivated in presence of rapamycin, and showed a decreased expression of of antigen uptake 
receptors137 (such as CD32, CD46, CD91 and CD205).  
To explain the potential role of mTOR in CD4
+
 T cell differentiation, professor JD. Powell's 
group selectively knocked out mTOR in T cells138. Interestingly, KO-mTOR CD4
+
 T cells fail to 
differentiate into Th1, Th2, or Th17 effector cells when cultured in appropriate conditions in 
vitro, rather they differentiate in Treg. Moreover these cells were accompanied by decreased 
STAT4, STAT3, and STAT6 phosphorylation in response to IL-12, IL-6, and IL-4, respectively. 
Pharmacological inhibition of mTOR signalling in naive CD4
+
 T cells by rapamycin treatment 
also facilitates the development of Foxp3
+
 Treg, and Foxp3
+
 CD4 T cells exhibit lower levels of 
mTOR activity than their effector counterparts. Interestingly, although genetic deletion and 
pharmacological inhibition of mTOR signalling can result in the induction of a large population 
of Foxp3
+ 
regulatory CD4 T cells in the absence of high concentrations of exogenous cytokines, 
this process is still dependent on the low levels of TGF-β found in serum-containing media. 
In murine animal model a prolonged rapamycin administration blocks the conversion of 
thymocytes from double-negative (CD4
-
CD8
-
) to double-positive T cells. However, although the 
absolute number of T cells is decreased, rapamycin administration does not alter the proportion 
of CD4
+
single-positive cells that up-regulate their expression of FOXP3 in the thymus. This 
indicates that the ontogeny of natural Treg cells is unaffected by mTOR blockade139. Like the 
ontogeny, even the Treg activation is mTOR independent. 
When stimulated in periphery by TCR and co-stimulatory molecules, T cells start to 
proliferate. The first checkpoint is progression from G0 to G1 phase of the cell cycle. For T cells 
and their progression in G1 phase the 2 activation signals are essential for PI3K and AKT 
engagement. When activated, they exert their action both on mTORC1 and mTORC2 complexes 
stimulating four pivotal essential processes for the progression from G0 to G1 phase. These are: 
increased mRNA translation, increased glycolysis and consequent ATP accumulation, 
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degradation of the cyclin-dependent kinase (CDK) inhibitor, p27, and promotion of IL-2 and IL-
2R expression. The further step, from G1 to S phase, is regulated by CDK proteins. Essential for 
this step is the stimulation through TCR and CD28, together with autocrine signalling by IL-2 
produced during progression through the first checkpoint. Of note, the PI3K–AKT–mTOR 
pathway is also involved in transmission of this IL-2R signal. So, mTOR-induced signalling 
might regulate the rate of initial cell cycle entry and the integration of sequential signals that are 
dictated by TCR and CD28 engagement and IL-2 production. Consequently, rapamycin blocks 
the T cells-cycle progression. However, it becomes dispensable at later stages, when large 
quantities of IL-2 are available. In these conditions, cell cycle progression by IL-2 seems to 
depend on the activity of the serine/threonine protein kinase PIM2140.  
As seen in the mice-thymus, rapamycin treatment doesn't affect Treg cell cycle progression 
and functional activity as well141. Interestingly, in kidney transplant recipients, only patients 
treated with rapamycin have a markedly increased frequency of CD4
+
CD25
+
FOXP3
+
 Treg cells 
compared with total CD4
+
 T cell numbers. The observation that rapamycin causes a generalized 
increase in the frequency of Treg cells is interpreted as the sum of two effects: 
1. ability of Treg cells to proliferate in the presence of rapamycin; 
2.  promotion of FOXP3 expression in peripheral T cells that are then converted into 
modulators of immune reactivity. 
1) The ability of regulatory T cells to proliferate when stimulated in the presence of 
rapamycin seems to be connected by two effects. First, Treg cells do not down-regulate 
phosphatase and tensin homologue (PTEN) expression after TCR engagement, which impedes 
the activation of the rapamycin-susceptible PI3K–AKT–mTOR pathway. Second, FOXP3 drives 
the expression of PIM2, reinforced by IL-2 and TCR-mediated activation of signal transducer 
and activator of transcription 5 (STAT5); PIM2 compensates for AKT inactivity and promotes 
cell cycle progression (Figure 6).  
2) When CD4
+
CD25
-
 T cells  are stimulated in vitro in presence of TGF-β and IL-2, the 
result will be the induction of FOXP3 expression142. This induction depend on the activation of 
the transcription factor SMAD3 (mothers against decapentaplegic homologue 3), which, together 
with TCR-induced NFAT, binds to the enhancer region of FOXP3 and promotes chromatin 
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remodelling that is necessary for translation. The AKT–mTOR pathway is a negative regulator 
of SMAD3, for this reason mTOR inhibition through rapamycin favours FOXP3 upregulation. 
Interestingly, when rapamycin is present at the time of transduction of constitutively active 
AKT, the inhibitory effect is lost. This implies that a rapamycin-sensitive signal involving AKT 
activation (and consequently, mTOR activation) is responsible for the control of peripheral 
FOXP3 induction. This effect is not restricted to FOXP3 and extends to approximately 50% of 
the genes that are modulated in response to TGF-β142,  which supports the view that conversion 
to a regulatory phenotype involves complex genetic reprogramming 
 
 
Figure. 6 Influence of mTOR pathway on cell cycle progression of T cells. a) In 
conventional T cells, mTOR integrates TCR and CD28 signals necessary to pass the 2 
checkpoints of T cell activation; transition from G0 to G1 phase (checkpoint 1v) and transition 
from G1 to S phase (checkpoint 2) of the cell cycle. b) Ability of Treg to proliferate when 
stimulated in the presence of rapamycin depends principally by the FOXP3-driven expression of 
PIM2, reinforced by IL-2- and TCR-mediated activation of STAT5. Derived from 
"Immunoregolatory function of mTor"136 
 
3.2   Pre clinical studies with regulatory T cells 
 
Several preclinical animal studies have established that the adoptive transfer of regulatory T 
cells can prevent various autoimmune diseases, acute and Chronic Graft versus Host disease and 
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favour the tolerance of graft transplantation. Autoimmune diseases are characterised by an 
activation of the immune system against self-antigen and for this reason Treg infusion inhibits 
ongoing T-cell responses and reverse established pathology. To date several pre-clinical studies 
are published using Treg for the treatment of autoimmune disease but the most promising 
strategy include the use of transgenic Treg expressing a T-cell receptor specific for the 
pathogenic antigen143,144. Overall these data indicate that the suppression of an ongoing 
autoimmune disease by Treg might only be feasible when these cells are specific for the 
pathogenic antigen. Alternatively, transfer of polyclonal Treg may cure ongoing disease only in 
lymphopenic hosts, in which the massive expansion could generate a sufficient number of 
antigen-specific Treg cells. From experimental data obtained in mice it is clear that Treg 
represent a potential new therapeutic modality for the control of GvHD. In a model of GvHD 
prevention using freshly purified Treg, Edinger et al145 showed a strong inhibition of expansion 
of donor T cells. However, the addition of freshly purified Treg had minimal or no effect on the 
acquisition of activation markers and IFN-γ production. In contrast, expanded Treg strongly 
inhibited the division and expansion of donor T cells and their capacity to express activation 
markers and produce IFN-γ. It was demonstrated that the in vitro activation of Treg led to an 
increase of their suppressive activity146 and probably this could explain why expanded Treg seem 
to have a more profound suppressive effect on the activation of donor T cells in an HSCT 
setting. GvHD is due to the early expansion and differentiation of alloreactive donor T cells. 
Because expanded Treg potently inhibit such activation, this explains their capacity to prevent 
the disease. There are some differences in the intensity of the effect of donor specific and 
polyclonal Treg. The former one have better effects rely on their increased ability to rapidly 
become activated in vivo and exert their immunosuppressive effect early after infusion. In 
support of this concept, it was recently showed that delaying Treg injection after day 4 was 
ineffective in treating GvHD147. Moreover, they also could display a suppressive effect mainly 
targeted to alloreactive donor T cells, whereas non-alloreactive donor T cells could be partially 
spared. The use of donor specific Treg dramatically reduced the expansion/differentiation of 
donor T cells and the percentage of IFN-γ-producing cells as well. The use of polyclonal vs 
antigen-specific Treg for the control of GvHD in allogeneic HSCT is an area of debate of intense 
interest. However, to date, we have only data from animal phase 1 trials using polyclonal 
expanded Treg. From animal data is possible infer that the use of high numbers of polyclonal 
Treg might achieve the same level of GvHD inhibition and promotion of immune reconstitution. 
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In fact, studies by Taylor et al148 demonstrated that by increasing the number of polyclonal-Treg 
(three Treg per infused allogeneic T cell), nearly complete inhibition of overt GvHD was durably 
achieved despite the presence of histopathological disease signs in target organs. Compared with 
mice receiving 10 × 10
6
 Treg, the injection of  50 × 10
6
 polyclonal Treg improved mainly 
immune reconstitution. However, in this latter group, immune reconstitution was less efficient as 
compared with mice receiving 10 × 10
6
 antigen specific Treg. Another aspect that has to be 
considered is the maintaince of the GVL; mouse model showed that both plyclonal and antigen-
specific Treg are able to maintain this essential mechanism145,149, however  this has to be studied 
in clinical trials.  
Treg are important even in the induction of tolerance to transplanted organs. They are present 
in tolerated allografts150, moreover animal data support this assertion through the demonstration 
that tolerance to a fully-mismatched transplant can be induced in the absence of pharmacological 
immunosuppression by Treg infusion151. The importance of Treg during the encounter with 
allogeneic tissues is perhaps best highlighted during pregnancy where a significant barrier to 
successful outcome is foetal carriage of paternally derived histocompatibility antigens. Foetal 
tissues are tolerated despite the persistence of maternal T cells alloreactive to paternal antigens 
throughout pregnancy152. This is the result of a complex interaction between foeto-maternal 
immune systems153 that includes a significant increase in the proportion of Treg, both locally 
(uterine) and systemically (spleen and lymph node). Since the primary function of Treg is the 
maintenance of self-tolerance, the question is whether their alloreactivity can confer an 
advantage in the context of transplantation following presentation of allogeneic antigen via 
direct, indirect or semi-direct pathway. Donor-specific Treg can prevent allograft rejection in 
murine transplant models154
,151,145 through a predominant effect on the indirect alloresponse155. 
The importance of specificity is suggested by experiments in which allospecific Treg of ABM 
mice (transgenic for a TCR specific for an intact class II molecule (I-Abm12)) could completely 
suppress rejection of cardiac allografts bearing their cognate but not third party antigens. These 
observations are supported by studies in autoimmune models showing that stable associations 
between Treg and DC precede inhibition of helper T cells156, suggesting that the APC, and 
cognate specificity, is central to the in vivo function of Treg. Induction of antigen-specific 
tolerance to fully allogeneic grafts by recruitment of Treg can also be achieved by administration 
of allogeneic splenocytes or MHC molecules via the mucosal route157. Absence of administered 
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splenocytes from local lymph nodes in these experiments suggests that Treg are recruited in an 
antigen-specific manner following presentation of the antigen via the indirect (or semi-direct) 
pathway158. While in vivo data demonstrate that indirect anti-donor allospecificity is a feature of 
Treg that mediate transplantation tolerance in experimental animals159 and in human renal 
allograft recipients as well160, in vitro observations indicate that Treg cannot be exclusively 
dependent on the indirect pathway of presentation since they are capable of suppressing the in 
vitro mixed lymphocyte reaction in which only direct allopresentation is available. Recent data 
resolves some of this dilemma by showing that Treg have both direct and indirect 
allosopecificity in vivo but that their regulatory function is several orders of magnitude more 
pronounced in allograft responses driven by the indirect pathway161.  
Treg are particularly attractive candidates for adoptive cell therapy to establish clinical 
transplantation tolerance particularly since they can be selected and expanded for a particular 
donor specificity in vitro162. However, human data in stable renal transplant recipients 
demonstrates that Treg do not significantly contribute to direct pathway hyporesponsiveness155 
and have a suppressive effect predominantly on the indirect anti-donor alloresponse163 which is 
not surprising given the three cell model described in section 1.2. As a result, expanded 
populations of allospecific Treg162 would not be expected to significantly alter the clinical 
response to the graft in the short term following transplantation without additional suppression of 
the direct pathway. 
 
3.3   Clinical Trials with regulatory T cells. 
 
To date, there are only few published results showing safety and feasibility of Treg infusion. 
However there are several ongoing clinical Trials evaluating the effects of this regulatory subset 
after solid organ transplantation, autoimmune disease and GvHD.  
The strategies used so far include the infusion of freshly isolated Treg and the infusion of ex-
vivo expanded Treg. The first clinical trial describing the infusion of expanded Treg was 
published in 2009164. They describe a procedure and first-in-man clinical effects of adoptive 
transfer of ex vivo expanded CD4
+
CD25
+
CD127
−
 cells for the treatment of GvHD. However 
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they treated only 2 patients affected by acute and chronic GvHD. In the patient with chronic 
GvHD, the major goal was the waning of steroids, which was supposed to alleviate some adverse 
effects of these drugs such as diabetes, musculoskeletal pain, and progression of osteoporosis. 
They achieved not only a reduction of steroids, but also significant improvement in the bronchial 
obturation to the level that bronchodilatators could be ceased. The results were less optimistic in 
the case of acute GvHD. However, it has to be highlighted that Treg were administered relatively 
late.  
In 2011 a clinical study were published by Brunstein et al.165. This could be considered the 
first phase 1 clinical study where the safety profile of umbilical cord blood (UCB) Treg was 
evaluated in 23 patients with acute GvHD. Patients received a dose of 0.1-30 × 10
5
 UCB 
Treg/kg. No infusional toxicities were observed  after infusion, and Treg were detected for 14 
days, with the greatest proportion of circulating CD4
+
 CD127
low 
FoxP3
+
 cells observed on day 
+2. Although this was only a phase I trial the authors affirmed that, compared with identically 
treated 108 historical controls, there was a reduced incidence of grade II-IV aGVHD (43% vs 
61%, P = .05) with no deleterious effect on risks of infection, relapse, or early mortality.  
In 2011 another trial was published by Di Ianni group166. The aim of this study was the 
infusion of freshly isolated Treg before HSCT to avoid the extensive ex vivo T-cell depletion of 
the graft, a mandatory procedure to prevent acute and chronic GvHD. This study demonstrated 
for the first time that adoptive immunotherapy with freshly purified CD4
+
CD25
+
 Treg 
counteracts the GvHD potential of a high number of donor Tcons in HLA-haploidentical HSCT. 
The surprising finding was the absence of GvHD in patients who received up to 1 × 10
6
 
Tcons/kg after an infusion of 2 × 10
6
 Treg.  
A new clinical trial from the University of Liegi (ClinicalTrials.gov Identifier: 
NCT01903473) is trying to assess the safety of the combination of donor Treg infusion and 
rapamycin administration (a non-standard immunosuppressor for this disease) in patients with 
steroid-refractory chronic GvHD. Patients who have refractory chronic GvHD will be eligible. 
They will be firstly treated with Rapamycin and after 3-4 weeks one infusion of  ≥ 0.5 x106 
Treg/kg is administrated. They are trying to take advantage of the rapamycin positive effects on 
Treg subsets increasing the Treg numbers usually reduced in c GvHD setting. 
53 
 
Treg adoptive infusion has been tested in patients affected by autoimmune disease since this 
subset of pathologies is characterised by a reduced number and/or defective Treg activity. In 
2014 a study testing the infusion of ex-vivo expanded Treg in diabetes Mellitus type 1 has been 
published by a group from Poland167. They presented  a prospective, non-randomised safety and 
efficacy pilot study of cellular therapy with ex vivo expanded CD4
+
CD25
high
CD127- Treg. The 
study aim was the restoring regulation in the immune system and the stop or at least delay the 
disease progress. Twelve Caucasian children with recently diagnosed diabetes were treated 
with ex vivo expanded autologous Treg. The general health and metabolic status of treated 
individuals were followed and compared at 4 and 12 months after infusion with 10 non-treated 
control patients matched for age, sex and disease duration. The administered Treg doses were: 
10 × 10
6
 Treg/kg in a single infusion (3 patients), 20 × 10
6
 Treg/kg in a single infusion (3 
patients), and 30 × 10
6
 Treg/kg in two infusions (6 patients). No severe adverse effects were 
observed in all the patients and the infusion was followed by an increase in peripheral blood 
Treg number. Interestingly, in 8 patients,  Treg administration resulted also in lower requirement 
for exogenous insulin  with two children completely insulin independent at one year. 
Treg are particularly attractive candidates even for adoptive cell therapy to establish clinical 
transplantation tolerance as well shown from pre-clinical studies. To date the most important 
clinical trials using Treg in solid organ transplantation are THE ONE STUDY 
(ClinicalTrials.gov Identifier: NCT02129881) and Thril (ClinicalTrials.gov Identifier: 
NCT02166177). They are a phase I clinical trials testing the safety and feasibility of Treg 
infusion in patients receiving respectively kidney and liver transplantation.  
THE ONE STUDY is a cooperative project to establish whether purified cells with 
regulatory activity can be used therapeutically to reduce the level of pharmacologic 
immunosuppression needed by recipients of transplanted organs. To assess this, several 
regulatory cell products will be tested: natural ex vivo expanded Treg, Mregs, Tr1 cells and DCs. 
In detail, the section of this project involving the use of nTreg is coordinated by the 
Immunereguation laboratory of King's College London. Autologous regulatory T cells will be 
grown under GMP conditions and re‐infused (1-10 million cells/kg) intravenously 5 days post 
renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and 
tacrolimus.  
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ThRIL is an open label, randomised, controlled and single ascending dose study, 
investigating the safety and tolerability of Treg immunotherapy after liver transplantation. 
Patients will be treated with ATG at time of transplantation, followed by Tacrolimus. Rapamycin 
will be started at 2 months, with an infusion of Treg at 3 months post transplantation. Two Treg 
doses will be tested, a low, 1.0x10
6
cells/kg and high, 4.5x10
6
cells/kg. The cohort of patients 
receiving the dose which is safe and well tolerated will be expanded to investigate an efficacy 
signal, providing the evidence required to take the development of Treg immunotherapy towards 
a larger Phase II/III study. 
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ISOLATION, CHARACTERIZATION 
AND REGULATORY T CELLS 
MANAGEMENT 
 
 
1. Introduction and Aims 
 
Solid organ transplantation represents a life-saving treatment for patients affected by end stage 
organ disease. Thought patient and graft survival rates for liver transplantation (LT) have 
reached 90% after 1 years, there are some side effects due to long-term immunosuppression. 
Although modern immune suppressive (IS) drugs have progressively reduced the incidence of 
acute rejection and transplantation-related mortality, their administration is associated with 
major side effects and potentially lethal toxicity, such as opportunistic infection, damage of 
transplanted organs and secondary cancer. Indeed, secondary malignancies are one of the leading 
causes of late mortality in LT recipients. Therefore, new treatment strategies aiming to improve 
long-term graft survival, decreasing IS therapy, and, ideally, inducing tolerance are needed. In 
the last years, immunomodulatory cell therapy has emerged as a promising therapy for the 
induction of tolerance after SOT. The major challenge is to achieve operational tolerance, 
defined as the absence of pathologic immune response against a graft, in an immunocompetent 
host, without maintaining protective responses against third party antigens. In this regard, 
regulatory T cells (Treg) have emerged as promising candidates for immunoregulatory cell 
therapy Treg have a pivotal role in maintaining peripheral immunological tolerance, by 
preventing autoimmunity and chronic inflammation. In animal models, several groups have 
shown that the infusion of freshly isolated or expanded Treg can prevent graft versus host 
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disease (GvHD) and both acute and chronic organ rejection after solid OT. In humans, a few 
clinical studies have been published reporting the infusion of Treg for the prevention of GVHD 
and autoimmune disease 166,167. These are phase-I trials showing safety of Treg infusion, however 
there are no published results testing the efficacy of Treg in OLT. In addition, even though liver 
is a privileged organ and differs from the others cause lower incidence of rejection, 
immunosuppressive regimens are still required. Recent data have shown that IS withdrawal 
coincide with the increase in the frequency of CD4
+
CD25hi T cells and FOXP3 transcripts in 
operationally tolerant liver transplant recipients.  However, to date, there aren't published results 
about freshly-isolated or ex-vivo expanded Tregs for the induction of tolerance in setting of solid 
organ transplantation. Moreover, the possibility to infuse cryopreserved Treg would highly 
improve the transplantation management and allow the use of these cells, for patients undergoing 
solid organ transplantation. So far, different cryopreservation and medium strategies have been 
reported in the literature, leading to inconclusive results168
,169,170. For these reasons, the aim of 
this chapter is to characterize the circulating Treg in healthy donors and in patients with end 
stage liver disease from a waiting list for liver transplantation.  
 
2. Material and Methods 
 
2.1 PBMC separation 
  
Peripheral blood (PB) of 8 healthy donors (HD) were provided by the "Centro Trasfusionale, 
Policlinico Sant'Orsola Malpighi" while  samples from 12 patients (Pts) were provided from the 
liver transplant waiting list at the Sant'Orsola Malpighi Hospital (Bologna). Patients with 
autoimmune liver disease,  HIV or RNA-positive Hepatitis C Virus infection were excluded. 
Blood was diluted 1 in 2 with PBS, before layered on top of 15mL of Ficoll-Hypaque 
(Amersham Bioscience, Piscataway, NJ), followed by centrifugation at 2000 rpm  at 20ºC for 20 
minutes with slow acceleration and no brake. Peripheral blood mononuclear cells (PBMC) were 
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derived from the harvesting of interface cells, followed by three washes with PBS at 2000 and 
1800 rpm twice respectively for 10 minutes at 4 ºC with normal acceleration and deceleration. 
 
2.2 Isolation of CD4
+
CD25
+
T cells 
  
CD4
+
CD25
+
 regulatory T cells were isolated using miniMACS CD4
+
CD25
+
 T Regulatory 
Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). The kit contains a cocktail of 
biotinylated antibodies and anti-biotin micro-beads for depletion of non-CD4
+
 T cells, and CD25 
micro-beads for subsequent positive selection of the CD4
+
CD25
+
 regulatory T cells. PBMC were 
incubated with 90μl Staining buffer and 10μl of biotin antibody-cocktail /107 cells for 10 
minutes, followed by 15 minutes incubation with anti-biotin micro-beads at 4 ºC. The biotin 
antibody-cocktail contained biotin-conjugated monoclonal anti-human antibodies against CD8, 
CD14, CD16, CD19, CD36, CD56, CD123, TCR γ/δ and CD235a (glycophorin A). The cells 
were then washed once with Staining buffer (centrifugation 1800 rpm for 5 minutes at 4 ºC) and 
resuspended in 500μl Staining buffer/108 cells. An LD MACS separation column was prepared 
by a single rinse with 2mL Staining buffer and placed on a MACS separator magnet. The 
resuspended cells were passed over the column and the negative fraction (unbound CD4
+
 cells) 
were eluted with a series of two x 1mL Staining buffer washes. Eluted cells were centrifuged and 
resuspended in 90 μl Staining buffer and 10 μl of CD25+ micro-beads/107 cells and incubated in 
the dark for 15 minutes at 4 ºC. These were then washed once with Staining buffer 
(centrifugation 1800 rpm for 5 minutes at 4 ºC) and resuspended in 500 μl Staining buffer /108 
cells. The cells were passed through an MS column and the negative selection (CD4
+
CD25
-
) 
eluted with a series of three x 500 μl Staining buffer washes. The column was removed from the 
magnet and the CD25-microbead-positive fraction, the CD4
+
CD25
+
 regulatory T cells, were 
eluted with 1mL of Staining buffer and firm column pressure from the plunger. After 
purification, the two separate fractions of CD4
+
CD25
-
 (Tresp) and CD4
+
CD25
+
 (Treg) were 
resuspended in RPMI 1640 medium (Lonza, Milan, Italy) supplemented with 10% heat-
inactivated FBS (Life Technologies-Invitrogen, Carlsbad, CA), 2 mM L-glutamine, 100 U/ml 
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penicillin, and 100 μg/ml streptomycin (MP Biomedicals, Verona, Italy). Treg were 
characterized by cytofluorimetric, functional and molecular analysis.    
 
2.3 Freezing and thawing 
 
Treg and Tresp were frozen in medium containing 50% AB plasma (healthy blood donor 
from Policlinico Sant’Orsola Malpighi), 40% CliniMacs buffer (Miltenyi Biotec, Bergisch 
Gladbach, Germany) and 10% dimethyl sulfoxide (DMSO). Cells were cryopreserved using 
Planer Kryo 560-16 (Planer Middlesex United kingdom) in a controlled-rate cryo-freezer and 
stored at -196° C in liquid nitrogen as previously reported
171
. After one month, samples were 
thawed rapidly  at 37°, transferred into a tube containing RPMI 1640 and then centrifugated once 
to remove DMSO. Viability was determined upon  thawing by Propidium Iodide (PI) assay. 
Briefly, cells were stained with PI, a fluorescent dye that binds to the DNA of dead cells, for 10 
minutes at 4 °C. According to cytofluorimetric analysis, the yield of viable Treg were calculated. 
Finally, cell concentration was adjusted to 10
6
 cells/mL in RPMI 1640.  
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Figure. 1  Scheme of the cycle used to freeze Treg. The temperature goes down following the 
10 steps procedure starting from 
+
10° till -140°C.  
 
 
2.4 Phenotypic analysis of regulatory T cells 
 
The phenotype of Treg cells was analyzed by flow cytometry FACSCantoII (Beckton 
Dickinson). For cell-surface staining, the following conjugated monoclonal antibodies were 
used: anti-CD45 Per-CP (HI30), anti-CD25 Biotin (4E3), anti-Biotin APC; anti-CD4 FITC (MT-
466), anti-CD127 PE (clone: MB15-18C9). All antibodies were purchased from Miltenyi 
Biotech. For intracellular staining, anti-human FoxP3 (PCH101) Staining Set PE Kit was used 
(eBiosciences), according to the manufacturer’s instructions. Isotype control rat IgG2 PE was 
used as a control (eBiosciences). Briefly, cells were surface stained if required, washed once in 
PBS and then vortexed and incubated in 1mL of Fixation/Permeabilization solution for 30 
minutes at 4ºC in the dark. Cells were then washed twice with Permeabilization buffer 1x and 
incubated with anti-human FOXP3 antibody for 30 minutes at 4 ºC in the dark. The cells were 
washed once with Permeabilization buffer 1x and resuspended in the same solution for FACS 
analysis. This phenotypic analysis was carried out on the PB of healthy donors and patients to 
evaluate number and percentage of circulating Treg. A lysis buffer from BD was used in order to 
lysate red blood cells. The same analysis was used on the 2 purified cell fractions after 
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immunomagnetic isolation, on both freshly and frozen cells to confirm the selected population. 
Lymphocytes were gated based on their forward and side scatter profile. The percentage of Treg 
was acquired by calculating the percentage of FoxP3
+
cells within the CD4
+
 CD25
+
 double-
positive cells. Recently, it was demonstrated that the IL-7 receptor CD127 is a reliable surface 
marker for Treg identification and isolation. CD127 is downregulated on all T-cells after 
activation, but not in effector and memory T-cells. For this reason, we can identify Treg with 
two different protocols. The first one allows the identification of CD4
+
 CD25
+
 FoxP3
+
 cells, 
while the second one avoids the need for intracellular staining and recognises the CD4
+
 
CD25
+
CD127
-
 populations. 
 
Figure. 2 Gating strategy used to characterize Treg cells pre and post thawing One 
representative experiment showing:  A) Dot-plot gating CD4 and CD25 suface markers; B)  Dot-
plot gating CD25 and FOXP3; C) Dot-plot gating CD25 and FOXP3 
 
 
A 
B C 
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2.5 Suppression assay 
 
To assess the inhibitory capacity of freshly-isolated and cryopreserved Treg, we set up a 
Mixed Leukocyte Reaction (MLR). 10
5
 Tresp were labelled with 5μ/mol Carboxyfluorescein 
succinimidyl ester (CFSE), according to the standard protocol. Next, they were co-cultured, for 4 
days, alone or with autologous and irradiated (3000 cGy) Treg at different Tresp:Treg ratios (1:2, 
1:4, 1:5, 1:10, 1:25). MLR was set up in flat-bottom 96-well plates pre-coated with anti-CD3 
mAb (5 μg/ml, clone UCHT1; BioLegend, San Diego, CA) in the presence of soluble anti-CD28 
mAb (5 μg/ml, clone CD28; BioLegend).  The suppressive capacity of fresh and thawed Treg 
was evaluated concomitantly. CFSE covalently binds the cytoplasmic components of cells and 
upon cell division is distributed equally between daughter cells. This feature is exploited to 
assess cell division by flow cytometry FACSCantoII (Beckton Dickinson). The capacity of Treg 
to modulate Tresp proliferation was analyzed using ModFit LT
TM
 3.1 calculating the Upper 
generation Proliferation Index, a measure of the increase in cell number over the course of the 
experiment for cells that are really proliferating (Figure 3).  
 
Figure. 3  Calculation of cell proliferation  by the CFSE staining method. Representative 
histogram of CFSE fluorescence analyzed using ModFit LTTM 3.1.  Every peak represent a cell 
generation as explained in the legend. A) Tresp in culture without Treg; B) Tresp in culture with 
Treg ( 1/4 Treg/Tresp ratio) 
 
2.6 Statistical analysis 
 
A B 
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Statistical analysis was carried out using GraphPad Prism software (GraphPad software Inc., 
USA). Parametric and non-parametric data were calculated as the mean±s.d. and median 
(interquartile range, IQR) respectively. For comparison of parametric and non-parametric data, t-
test, one- or two-way ANOVA with Bonferroni test comparison and Kruskal-Wallis test were 
used where appropriate. 
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3. Results 
 
3.1 Enumeration of regulatory T cells in Peripheral blood 
 
Clinical applications based on Treg infusions require high numbers of active and suppressive 
cells. For this reason the assessment of the CD4
+
CD25
high
 FoxP3
+
 population will be useful to 
better understand the starting number of cells present in PB and yields after cell-processing. 
Moreover assessing the number of circulating Treg will be useful in order to choose the best cell 
source from either PB or leukapheresis. 
First, we compared percentages and absolute numbers of circulating Treg in both healthy 
donors and patients waiting for LT. One million cells from PB were stained (see material and 
methods) and the percentages of lymphocytes, CD4
+
CD25
+
, CD4
+
CD25
high
 and CD4
+
CD25
high
 
FOXP3
+
 T cells were evaluated. As shown in Tables 1 and 2 the mean percentage of 
CD4
+
CD25
high
 FOXP3
+ 
T cells
 
was not significantly different  between patients (0.55%±0.23 
n=12) and HD (0.44±0.13 n=8). Although the relative percentage of Treg in white blood cells 
(WBC) tends to be slightly higher in patients, their cognate absolute numbers are actually lower 
(29.8±5.61 vs 25.13±9.92 cells/μL) than those retrieved in healthy donors. This is due to the 
leukopenic status of these patients  (7050±1220 vs 4950±2010 WBC/μL) (Figure.4). When we 
identified Treg by the use of CD127 surface marker, once again the mean percentage of 
CD4
+
CD25
+
CD127
-
 cells of patients  (0.74±0.27%) was not significantly different from the 
normal counterparts (0.85±0.26%). 
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HD 
 
Lymphocyte 
% 
CD4
+
CD25
+
 
% 
CD4
+
CD25
high
 
% 
CD4
+
CD25
high
 FOXP3
+
 
% 
1 38.6 3.1 0.7 0.6 
2 29 4.7 0.9 0.5 
3 22.5 4.7 0.6 0.3 
4 29 4.8 0.9 0.3 
5 30 3 0.8 0.5 
6 32 5.7 0.9 0.3 
7 22.4 3 0.7 0.6 
8 27.6 3.3 0.6 0.4 
Mean 28.89 4.04 0.76 0.44 
St. Dev 5.21 1.06 0.13 0.13 
 
Table. 1  Peripheral Blood evaluation in healthy donors. Percentage of lymphocytes, CD4
+
CD25
+
, 
CD4
+
CD25
high
, CD4
+
CD25highFOXP3
+
 in the circulating white blood cells fraction was evaluated by 
flow cytometry analysis. 
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Liver Patients 
 
Lymphocyte  
%  
 CD4
+
CD25
+
  
% 
CD4
+
CD25
high
  
% 
 CD4
+
CD25
 high
 FoxP3
+
  
%  
1 39 9.7 1.5 0.9 
2 14 2 0.4 0.2 
3 24.5 3.6 0.7 0.4 
4 28.6 7 1 0.7 
5 23 7.5 0.9 0.6 
6 15 2.6 0.3 0.3 
7 20 3.7 0.6 0.5 
8 18 5.6 0.7 0.4 
9 30 6.8 0.8 0.4 
10 20 5.9 1 0.9 
11 15.5 7 0.6 0.5 
12 4.9 4 0.8 0.8 
Mean 21.04 5.45 0.78 0.55 
St. Dev 8.86 2.29 0.31 0.23 
 
Table. 2  Peripheral Blood evaluation in patients from waiting list for liver transplantation. 
Percentage of lymphocytes, CD4
+
CD25
+
, CD4
+
CD25
high
, CD4
+
CD25highFOXP3
+
 in the circulating white 
blood cells fraction was evaluated by flow cytometry analysis. 
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Figure. 4  Circulating cells. Number of circulating A) Treg and B) WBC in healthy donors and liver 
patients.     
 
 
3.2 Isolation of CD4
+
 CD25
+
  cells.  
 
Subsequently, we isolated Treg from PBMCs by a two-step immunomagnetic selection. First, 
CD4
+
 cells were separated by depletion from PBMCs followed by enrichment in CD25
+
 fraction. 
After selection, cell purity was assessed by flow cytometry. In healthy donors, 90.69±3.62% 
were CD4
+
CD25
+
 cells with 89.6±4.72% of cells expressing FOXP3, while in patients this was 
88.61±4.99% and 91.9±4.37%, respectively (Figure 5). Analysis of the Tresp fraction showed a 
percentage of FoxP3
+
 cells < 8% in both patients and healthy donors (6.44±3.3% and 
5.03±0.16%) respectively.  
The high purity of the Treg fraction was confirmed by CD127-staining since the percentage of 
CD4
+
CD25
+
CD127
-
 was 83.8±3.96% and 81.3±8.7% in healthy donors and patients respectively 
(Figure 5). 
A B A B 
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Figure. 5 Phenotypic evaluation of Treg after immunomagnetic isolation. Each dot represents one 
evaluation showing the CD4
+
CD25
+
 , CD4
+
CD25
+
FoxP3
+
 
 
and CD4
+
CD25
+
CD127
-
  expression in healthy 
donors, panel A, and patients, panel B, obtained using flow cytometry. 
 
3.3 Regulatory T cells are viable and maintain their phenotype after thawing  
 
Highly purified Treg and Tresp fractions were stored using a controlled rate cryo-freezer and 
afterwards stored in liquid nitrogen. After a month, cells were thawed at 37° followed by a 
centrifugation in RPMI 1640 to eliminate DMSO and re-stained to assess viability, as well as 
FOXP3 and CD127 expression.   
Viability was evaluated by PI test. Viable cells were 88.17±5.41% in healthy donor Treg, while 
in patients the average percentage was 86.57±4.24%.  
The second steps provided the FOXP3 evaluation because previous studies168
,169,170 reported 
decreased expression of this marker post-thawing. 
In this experimental system Treg maintain their phenotype based on the expression of FOXP3 
marker. In fact no significative difference in FOXP3 expression was founded between fresh and 
thawed cells. (Figure 6) 
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Figure. 6 Phenotypic evaluation of Treg pre and post thawing. CD4+CD25+ and CD4+ CD25+ 
FoxP3
+
 expression determinated by flow cytometry in freshly isolated and thawed Treg fractions. Results 
show the mean percentage of CD4
+
CD25
+
 and CD4
+
 CD25
+
 FoxP3
+  
pre e post thawing from healthy 
donors, panel A, and patients, panel B 
 
 
Moreover, no significant differences were found when the mean intensity of fluorescence (MFI) 
of FOXP3 between fresh and thawed cells was compared. In detail, in healthy donors the MFI is 
5109±2642 in fresh samples and 4163±2109 after thawing, while in patients this is 8091±2820 
and 5768±1456 respectively. To confirm this data Treg were analysed for CD127 expression. 
Once again, no significant differences were observed between fresh and thawed cells as shown 
in figure 7. 
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 Figure.7 Phenotypic evaluation pre and post thawing. CD4
+
 CD25
+
 CD127
-
 expression determinated 
by flow cytometry in freshly isolated and thawed Treg. Results showt he mean percentage of CD4
+
CD25
+
 
CD127
-  
pre and post thawing from healthy donors, panel A, and patients, panel B 
 
3.4 Evaluation of suppressive ability  
 
To assess the function of isolated Treg before and after cryopreservation, we set up MLR.  
Autologus Tresp labelled with CFSE and stimulated with anti-CD3 and anti CD28 were cultured 
alone or with different ratios of Treg for 5 days. At the end of the co-culture cells were harvested 
and fluorescence intensity was analysed by flow cytometry. Fresh and thawed Treg activity was 
tested using a fresh autologous Tresp population at different Treg/Tresp ratio.  
As shown in figure 8 freshly isolated Treg from patients and healthy donors efficiently reduced 
Tresp proliferation in a dose-dependent manner. Even though the differences are not significant.  
Treg from patients at a high ratio (Treg/Tresp 1/4) showed a reduced suppressive ability 
compared to healthy donors.  
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Figure 8 Suppressive ability of freshly isolated Treg. Co-culture (4 days) of autologous Treg with 
CD4
+
 CD25- (Tresp) stimulated with anti-CD3 and anti CD28 (5ug/ml) and labeled with CFSE. FOLD-
CHANGE was calculated as ratio between the” upper generation proliferation index” of Tresp cultured in 
the presence of increasing ratios of Treg and the” upper generation proliferation index” of CTR culture 
where no Treg were added. Panel A and B show the suppressive function of freshly isolated Treg from 
HD and patients respectively; ** p< 0.01 * p< 0.05 referred to CTRL condition  
 
 
The next step was the evaluation of the suppressive ability of Treg after thawing. Samples were 
thawed rapidly  at 37°C, transferred into a tube containing RPMI 1640 and then centrifugated 
once to remove DMSO. Subsequently cells were cultured at different Treg/Tresp ratio.  
Treg from healthy donors, had a reduced suppressive ability compared to freshly isolated Treg, 
especially when high ratios were compared (proliferation fold change at a 1/4 ratio were 
0.49±0.15 vs 0.79±0.04; p<0.05, respectively). Thawed Treg from patients were unable to 
suppress the proliferative activity of Tresp, even at increased Treg/Tresp ratio. (Figure 9)      
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Figure 9 .Suppression abibity of  thawed Treg. Co-colture (4 days) of autologous Treg with CD4
+
 
CD25- (Tresp) stimulated with anti-CD3 and anti CD28 (5ug/ml) and labeled with CFSE. FOLD-
CHANGE was calculated as ratio between the” upper generation proliferation index” of Tresp cultured in 
the presence of increasing ratios of Treg and the” upper generation proliferation index” of CTR culture 
where no Treg were added. Panel A and B show the suppressive function of  thawed Treg from HD and 
patients respectively; ** p< 0.01 * p< 0.05 referred to CTRL condition 
 
3.5 Yields  
Given the low Treg numbers present in PB it is very important to understand how many cells we 
recover during the different steps of cell processing. For this reason, in compliance with the 
cytofluorimetric analysis we calculate the number of recovered cells after thawing to get the final 
yield and understand the feasibility of our method.   
After the immunomagnetic-selection, cells were counted and cell number was adjusted in 
compliance with viability and the percentage of CD4
+
 CD25
+
 FoxP3
+
 cells assessed by flow 
cytometric analysis. To test the cryopreservation protocol cells were frozen using a controlled 
rate cryo-freezer. Controlled-rate freezing before long-term sample storage is a vital step in the 
cryopreservation procedure, since the rate at which cells are cooled has an extremely significant 
influence on cell survival. Yield was then calculated considering the numbers of recovered cells, 
according to CD4
+
 CD25
+
FOXP3
+
 and viability analysis. Yield after thawing is 75 ±12.5% in 
HD but dropped to 59±10% in patients. (Figure 10) 
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Figure. 10  Yield after thawing. Mean percentage of recovered cells after thawing calculated 
considering the numbers of stored and recovered cells according to CD4
+
 CD25
+
FOXP3
+
 and viability 
analysis. 
 
 
4.  Discussion 
 
Cell therapy has emerged in the last years as a promising therapy for the induction of tolerance 
after organ transplantation. Major challenge is to determine whether cellular therapy makes the 
immune microenvironments permissive to graft tolerance and, specifically, whether it can 
improve solid organ and HSCT outcomes through anti-inflammatory effects and the induction of  
immune tolerance.  
The use of CD4+CD25+FOXP3+ regulatory T cells (Treg) as a cellular therapy is an attractive 
approach for autoimmunity disease, GvHD and for limiting immune responses to allograft after 
transplantation. Possibility of avoiding or minimizing the use of immunosuppressive drugs will 
positively impact on most of treatment-related complications, such as infections, cardiovascular 
diseases, diabetes, renal failure, neurological complications and secondary cancers.  
Cell therapy using Treg is not yet fully accomplished cause of several problem regarding: 
selection of a pure cell fraction, effective cell dose, use of freshly isolated or ex-vivo expanded 
cells, possibility to cryopreserve the purified product or expanded Treg-fraction and use of 
alloantigen-reactive or polyclonal Tregs.  
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The first question of this work concerned the evaluation of the amount of Treg available for cell 
therapy in PB of studied group. In the analysed set of patients the percentages of Treg tend to be 
slightly higher than HD (0,55% vs 0,44%, Table 1 and 2) nevertheless the absolute number is 
lower because of their leukopenic status (29.8±5.61 vs 25.13±9.92 cells/μL) (figure 4). This 
result confirms what Julia Almeida et al. have found in patients with alcohol-related disease172. 
They analyzed patients with alcoholic related hepatitis correlating the Treg reduction with the 
dysregulation of cytokine modulating proliferation and/or Treg survival.  
These results show that the amount of Treg present in PB and leukapheresis are not enough for a 
clinical trials with high cell numbers. Normally after a leukapheresis procedure (without 
mobilization with G-CSF) the amount of white blood cells is around 10x10
9
; considering the 
percentages of Tregs previously reported the number of cells available for cell therapy will be 
around 50x10
6
 therefore not enough for a clinical trial. 
A possible solution is provided by PB mobilization with G-CSF as shown by Ukena SN et al in 
Hematopoietic Stem Cell donors173. Low Treg numbers can be implemented, exploiting the 
capacity of G-CSF application to lead a numerical increase of circulating Tregs without 
modification in their suppressive activity and phenotype. However, this strategy does not appear 
to be enough to recover a number of cells necessary for the infusion of more than 3x10
6 
cells/Kg, 
leaving ex vivo expansion as the only possible strategy.   
In a cell therapy protocol with Treg, cryopreservation is important because it can overcome 
several issues. This approach would allow for more flexibility in terms of planning the therapy, 
timing of the infusions, and also allow for subsequent Treg infusions, regardless of 
pharmacological treatment applied after the first infusion. 
For this reason, Treg stored in advance can be used when necessary, and this possibility can be 
exploited during the follow-up of forthcoming clinical trials to stock samples for future analysis. 
Therefore, in this research work phenotype and function of freshly isolated Treg, before and after 
cryopreservation has been tested. Data show that thawed cells, both in controls and patients, 
maintain their phenotype (figure 6 and 7), while only thawed Treg from patients lose their ability 
to suppress proliferation in vitro. To date, contrasting results have been published about the 
feasibility of Treg cryopreservation. The first evaluation on cryopreserved Treg, made by Dr. 
Elkord168, found a significant reduction of CD4
+
CD25
+
FOXP3
+
 cells after thawing. Conversely, 
Venet and Van Hemelen have shown that cryopreservation did not alter the percentage of Tregs 
in HIV-patients and HD169174. In these reports, PBMC freezing protocols included different 
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cryopreservation media and Treg detection strategies; Elkord’s group evaluation was made on 6 
HD using a medium composed by 90% FBS and 10% of DMSO. In contrast, Venet’s group 
analyzed 17 HIV-infected patients and no significant differences in the percentage of CD4+ 
CD25+ CD127- cells were founded, however they used a different medium, consisting in 60% 
human serum AB, 30% RPMI 1640 and 10% of DMSO.  
In this project a controlled rate cryo-freezer has been used and a new medium for 
cryopreservation (GMP compliant) composed by 50% human AB serum, 40% CliniMacs buffer 
and 10% DMSO, was purposed. After thawing, cell viability was 88.2%±5.41 in HD and 
86.6±4.24 in patients, and, most importantly, in both groups a high expression of FOXP3 was 
preserved in thawed Treg cells (figure 6). However when patient Treg were tested in vitro they 
were not able to suppress proliferation of CD4+ CD25- (figure 9). This result confirmed what 
Peters et al. found in Treg isolated via CliniMACS and then stored in liquid nitrogen175. After 
thawing, Treg showed 70–80% viability but their suppressive capacity was impaired and not  
regained by cell resting for up to seven days in culture medium. Only Treg expansion was able to 
restore their suppression ability.  
In fact, a possible solution might be the use of rapamycin-expanded Treg because, compared to 
freshly isolated fraction, they are more suppressive both in vitro and in vivo. A study comparing 
freshly isolated Treg with the expanded counterpart showed that after expansion, Treg increased 
the intracellular CTLA-4 and GITR expression.  
Moreover the expansion procedure breaks the anergic Treg-status by the use of high IL-2 doses 
and antiCD3/CD28 beads and rapamycin, with its capacity to select the regulatory population, is 
essential for Treg function. In fact, in type 1 diabetic patients, freshly isolated CD4+CD25+ 
Tregs are characterized by a reduced suppressive ability that is recovered after expansion in the 
presence of rapamycin128. Previous works studying Treg management found that freezing and 
thawing did not adversely affect the function of expanded third-party Tregs since they 
effectively prolonged embryonic pig pancreatic graft survival and function in C57BL/6 mice for 
up to 8 weeks post-implantation, similarly to freshly isolated Tregs176. A more detailed study 
showed that human Tregs, which were massively expanded by stimulation with APCs and 
subsequently frozen, maintained suppressive function in vitro after thawing177.  
In conclusion these results show that Treg expansion is a necessary procedure especially for 
patients; it increases the Treg number available for adoptive cell therapy and solves the problem 
due to freezing procedure.     
75 
 
EXPANSION OF REGULATORY T 
CELLS UNDER GOOD 
MANUFACTURE PRATICE 
CONDITION 
 
 
 
1. Introduction and Aims 
 
The above described results have been important to demonstrate that the isolation of Tregs from 
PB will not be sufficient to obtain the numbers of Tregs necessary for a clinical trial, both in 
solid organ transplantation and GvHD. In addition, after cryopreservation, the yield was high and 
the cells maintained their phenotype, even though reducing their suppressive capacity. For this 
reason, the ex vivo expansion of regulatory T cells is needed to obtain the sought cell product. 
Thus far is possible to find in literature only works showing Tregs expansion in healthy donors 
using antiCD3/antiCD28 beads in presence of rapamycin and IL-2178 for this reasons the aim of  
this part was to develop a protocol for HD and liver patient Treg using reagents respecting the 
Good manufacture Practice (GMP). The expansion will be useful to obtain a therapeutic Treg 
number (more than 3x10
6
 cells/kg) that could be used for the infusion in clinic after solid organ 
transplantation or for the treatment of GvHD.  
 
2. Material and Methods  
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2.1 CD4
+
CD25
+
 Isolation 
 
The isolation of the CD4
+
CD25
+
 population has been effectuated in 2 steps, CD8 depletion and 
subsequent CD25 enrichment. This procedure differs from that one used in the previous section 
because no GMP compliant biotin antibody cocktail and anti-biotin antibody cocktail are 
available on the market.  
Peripheral blood (100 mL) (PB) of 3 healthy donors were provided by the "Centro Trasfusionale, 
Policlinico Sant'Orsola Malpighi" while samples from 3 patients from the liver transplant 
waiting list at the Sant'Orsola Malpighi Hospital (Bologna) were provided by the Surgical Unit. 
PBMCs were isolated as described in paragraph 2 section 2.1 and then resuspended in MACS 
buffer, at 10 ml/10
9
 total cells. Afterwards they were incubated with CD8 microbeads, 750 
μL/109 total cells, for 30 minutes in the dark at room temperature, on a roller. Post incubation, 
the bead bound cells were washed in MACS buffer by adding 1-2ml of MACS buffer for 10
7
 
cells and centrifuged at 1800 rpm for 10 minutes. Subsequently the supernatant was completely 
aspirated. The cells were next resuspended in 500μl of MACS buffer per 108 cells and 
subsequently passed through MACS LS columns contained within a magnet to remove the CD8 
microbead labeled cells. Of note, the LS columns were prepared prior the application of the cell 
suspension, by rinsing with 3ml of MACS buffer. Post application of the cell suspension onto the 
column, the unlabeled cells were collected below and the column washed three times with 3 ml 
of MACS buffer. The effluent, containing the unlabeled cells, was collected and washed with 
MACS buffer. After that, cells were resuspended in MACS buffer (20 mL/10
9
 total cells) and 
incubated with CD25 microbeads (750 μL/109 total cells) for 15 mins at 4oC in the dark. Cells 
were next washed with MACS buffer, by adding 1-2ml of buffer per 107 cells and centrifuged at 
1800 rpm for 5 minutes. The cells were next resuspended in 500μl of MACS buffer per 108 cells 
and passed through MACS LS columns contained within a magnet, to isolate CD25 microbead 
labeled cells. Of note, prior to the application of the cell suspension, the column was placed in 
the magnetic field of a suitable MACS separator and rinsed with 3ml of MACS buffer. Post cell 
application of the cell suspension onto the column, the column was washed with 3ml of MACS 
buffer three times. Subsequently the column was removed from the magnet and placed on a 
suitable collection tube. The labeled cells within the column were plunged through with 2 mL of 
MACS buffer. The CD25 microbead labeled cells were subsequently washed in staining buffer 
and purity assessed by flow cytometry. 
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2.2 Regulatory T cells expansion using GMP reagents 
 
Tregs were isolated as previously described (section 2.1). CD4
+
CD25
+
 Tregs were then plated at 
1 x 10
6
 cells/ml, on 24-well flat bottom plates in culture media, TexMACS GMP Medium 
(Miltenyi Biotech), supplemented with 5% human AB serum (HS), and expanded in presence of 
100 nM GMP rapamycin (Miltenyi Biotech). Cells were polyclonally activated with anti-CD3 
and anti-CD28 coated beads (Miltenyi Biotech) at a 4:1 bead:cell ratio and cultures 
supplemented with IL-2 (1000 IU/mL) 2 days post-activation and replenished every 2 days 
thereafter. Cells were restimulated every 7 days by magnetically removing the activation beads 
and adding fresh beads (1:1 bead:cell ratio), rapamycin and IL-2. The expansion period was 
limited to 21 days with concurrent assessment of Treg phenotype and function (described in 
paragraph 1 section 2.4 ) 
 
2.3 Flow Cytometry analysis 
 
The following monoclonal antibodies were used: anti-CD25 Biotin (4E3), anti-Biotin APC; anti-
CD4 FITC (MT-466), anti-CD127 PE (clone: MB15-18C9), anti-CD8 (SK1). anti-CD196 
(11A9), anti-CD161 (DX12), anti-CD3 (Leu-4), anti-CD56 (NCAM-16), anti-CD19 (4G7), anti-
human FoxP3 (PCH101) and anti-CD14 (MФP9) 
 
3. Results 
 
3.1 Regulatory T cells expansion in patients and healthy donors 
 
After isolation cells were resuspended at 10
6
/mL in TexMacs and stimulated with 
antiCD3/CD28 beads plus rapamycin (100nM) and IL-2 (1000U/mL). At the end of every cycle 
they were counted, re-stimulated with beads (beads/cells ratio 1:1) and re-plated in the presence 
of IL-2 and rapamycin. Analysis of the Fold increase (Figure 1B), demonstrated that cell 
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expansion reached a peak between the second and third re-stimulation. The same analysis 
showed that the mean fold increase expansion after 21 days of culture is 559 (342-826) with a 
great donor variability. Of note, a therapeutic cell numbers was reached in every sample (figure 
1A) 
 
 
Figure. 1 Ex vivo Treg expansion from healthy donors. A) Treg cell lines were stimulated with anti-
CD3/CD28 beads and IL-2 (1000 IU/mL) in the presence of Rapamycin (100nM). Cell counts were 
performed at weekly intervals (DAY) throughout culture period. B) The in vitro expansion of 3 different 
Treg cell lines was calculated as Fold increase (number of cells at each time point divided for starting 
Tregs number). 
 
Subsequently the expansion ability of patient Treg was evaluated. Following the same expansion 
procedure cell numbers and Fold Increase were evaluated. Although Treg from patients were 
able to expand in culture (Figure 2A and B), they did not reach the same expansion rate when 
compare with the HD counterpart (Mean fold increase 559 vs 255 respectively in HD and Pts).  
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Figure. 2 Ex vivo expansion of Treg from Patients in waiting list for liver transplantation. A) Treg 
cell lines were stimulated with anti-CD3/CD28 beads and IL-2 (1000 IU/mL) in the presence of 
Rapamycin (100nM). Cell counts were performed at weekly intervals (DAY) throughout culture period  
B) The in vitro expansion of 3 different Treg cell lines was calculated as Fold increase (number of cells at 
each time point divided for starting Tregs number). 
 
3.2 Phenotypic evaluation of expanded cells 
 
Human Treg cells have been shown to be an heterogeneous population in the expression of 
specific cell markers. In order to investigate if the expansion procedure was effective in 
promoting phenotypic signatures on these cells, the percentage of CD4
+
CD25
+
, 
CD4
+
CD25
+
FOXP3
+
 and CD4
+
CD25
+
CD127
-
 fraction was evaluated at day 0 and at each time 
point both in patients and healthy donors. Flow cytometric analysis in figure 3 shows that at day 
0 the population is not highly pure because the mean percentages of CD4
+
CD25
+
FOXP3
+
 cells 
were 65.3±13.3 and 61.4±4.6 respectively in HD and Pts. Data confirmed by CD127 analysis 
(figure 3). However after the 21 days expansion procedure all the cells were 
CD4
+
CD25
+
FOXP3
+
 and CD4
+
CD25
+
CD127
-
.  
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Figure.  3 Phenotypic analysis of Treg cells from  healthy donors and patients during 21 days 
expansion.  Percentage of expression of CD4
+
CD25
+
, CD4
+
CD25
+
FOXP3
+
 and CD4
+
CD25
+
CD127- was 
calculated by flow cytometry at Day 0,7,14 and 21 in HD (panel A) and Pts (Panel B) respectively. 
 
 
Since at Day 0 cell fractions didn't show an high purity the evaluation of cell contaminants was 
necessary in order to understand the components of the cell product. Cells at day 0 and at each 
time point were stained with markers specific for monocyte (CD14), T helper 17 (CD4, CD161 
and CD196), CD8, B lymphocyte (CD19) and T NK (CD3 and CD56). As Shown in figure 4, 
both cells from healthy donors (Panel A) and patients (Panel B) present contamination, 
especially Th17 and B lymphocyte. However at the end of expansion no contaminants were 
observed.  
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Figure. 4 Phenotypic analysis of freshly isolated and ex vivo expanded Treg from  HD  and patients. 
Percentages of CD14, CD8, CD19, Th17 and T NK cells were calculated by flow cytometry analysis at 
Day 0,7,14 and 21 in HD (panel A) and Patients (Panel B). 
 
 
 
3.3 Functional evaluation of expanded cells 
A B 
A B 
A B 
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To compare the regulatory function of each Treg cell line preparation, responder CD4
+
CD25
-
 T cells were 
stained with CFSE as described in Material and Methods (Paragraph 1 section 2.5) and stimulated with 
anti-CD3/CD28 antibody in the presence or absence of expanded Treg at different ratios. After 4 days of 
co-culture, the ability of the different Treg cell lines to suppress a polyclonal stimulus was determined by 
CFSE dilution using flow cytometry. As depicted in figure 5, after 21 days of expansion both Treg from 
healthy donors and patients were able to suppress Tresp proliferation and no significant differences were 
observed between patients and controls. 
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Figure 5 Suppressive Treg ability after 21 days expansion. Co-culture (5 days) of CD4
+
 CD25- 
(Tresp) stimulated with anti-CD3 and anti CD28 (5ug/ml) and labeled with CFSE with different Treg 
ratio. Data are expressed as average percent of suppression of Tresp proliferation ±1SD.  
 
 
4. Discussion  
 
Treg expansion is the best choice in clinical trials using highly suppressive T-cell179. However, to 
date, there are some issues concerning the use of antigen-specific or polyclonal Treg. Antigen-
specific Treg, as shown in literature, are known to be effective at lower cell doses and thus may 
be preferable for tolerance induction strategies however the develop of a clinical protocol for cell 
therapy with these cells is complex. A possible strategy could be the use of antigen-presenting 
cells to differentiate an antigen-specific Treg subset ex vivo. This procedure, already published, 
cannot be used in clinic due to the lack of a GMP-compliant isolation procedure able to select a 
pure Treg population180.  
For this reason, approaches using polyclonal Treg are likely to be more universally applicable.  
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To date, adoptive transfer of freshly isolated human Tregs has prevented GvHD in patients 
treated with allogeneic hematopoietic stem cell transplantations partially depleted of 
conventional T cells. However, T cell–replete grafts are more commonly used, and prevention of 
GvHD after T cell–replete transplantations require the transfer of a higher number of Tregs that 
can only be obtained through ex vivo expansion.  
Here it has been shown how Treg can be expanded by more than 500-fold (figure 2) by anti-CD3 
and anti-CD28 coated beads, IL-2 and rapamycin. Despite high variability in liver patients, the 
resulting fold increase is useful to set up a clinical trial using more than 3x10
6
 cells.  
Phenotypic analysis demonstrates that the cell profile changes during expansion; the 
contaminants found at day 0 were principally CD19+ and CD14+ cells. However, their 
expression was already reduced after 7 days and at the end of expansion the percentages of all 
the non-regulatory T-cells was less than 1 % (figure 4). The achievement of this purity, obtained 
exploiting the positive effects of rapamycin, is mandatory for a cell therapy protocol inducing 
tolerance. Rapamycin is essential to obtain a pure and highly suppressive population. As 
previously explained  (section 3.1; general introduction), only Treg are able to proliferate when 
rapamycin is added in culture, because they are not dependent on the PI3K-AKT-mTOR 
pathway for cell cycle progression. Moreover, mTOR-blocking promotes FOXP3 expression in 
T-cells, which are then converted into modulators of immune reactivity.  
Data from this thesis show that expanded cell, from both control and patients, highly express the 
FOXP3 marker. In addition, Treg purity was further confirmed by CD127 evaluation and after 
21 days of expansion, cells do not express CD127 (figure 3). Phenotypic evaluation is 
strengthened by the functional analysis where Treg from HD and patients are highly suppressive 
(figure 5)      
The results obtained in this thesis confirm what several published works have previously shown 
in healthy donors and patients with autoimmune disease about the positive effect of expansion on 
Treg extending the possibility to expand Treg from patients with liver diseases.  
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IMPACT OF 
IMMUNOSUPPRESSIVE DRUGS ON 
EX VIVO EXPANDED REGULATORY 
T CELLS 
 
 
1. Introduction and Aims  
 
Immune suppressive regimen in clinical transplantation and GvHD plays the crucial role to 
dampen down the immune response and allow graft survival. These powerful 
immunosuppressive drugs efficiently control acute graft rejection. However, because of their 
non-specificity the constant use of this therapeutic approach presents adverse effects and fails to 
control chronic rejection. To this aim various compounds have been developed and selected 
according to their ability to control lymphocyte activation.  
Conventional immunosuppressive therapy employs a calcineurin inhibitor such as cyclosporine 
(CsA) or tacrolimus (Tac), as well as corticosteroids and mycophenolate mofetil (MMF) to 
control immune responses. At the moment, successful organ transplantation still requires long 
term treatment with diverse combinations of these drugs responsible of several side effects.    
Although their precise molecular mechanism of action is well characterized, little is known 
regarding the effect on specific T cell subsets and ultimately their capacity to influence Treg 
viability and function.  
Current evidence suggests that calcineurin inhibitors have markedly negative effects on Treg, 
mainly by interfering with the IL-2 production and therefore affecting Treg function and 
survival. Conversely, corticosteroids have been reported to increase Treg frequency and FOXP3 
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expression in patients with autoimmune diseases. Finally, patients receiving MMF show 
significantly higher CD4
+
CD25
hi
FOXP3
+
 Treg compared to patients on other treatments. 
Furthermore, studies on patients with renal impairment showed that MMF may reverse the effect 
of anti-calcineurin treatment on Treg, maintaining their functional activity in vitro.   
Ex vivo rapamycin expanded Treg are a potential tool for promoting allograft tolerance after 
organ transplantation and for GvHD treatment. However, all the in-vivo studies published so far 
and in the ongoing clinical trial of solid organ transplantation these cells will be injected in 
combination with the immonusuppressive drugs.  
Although none of the immunosuppressive drugs have been specifically designed to influence 
Treg, they nevertheless do so through various pathways. In addition, there are no data showing 
the effect of the immunosuppressive regimen on Tregs expanded in vitro. In this chapter the 
effects of Tac, MMF and methyl-prednisolone on viability, proliferative capacity and function of 
in vitro expanded Tregs has been investigated. 
 
 
2. Materia land Methods  
 
2.1 Cell isolation and separation 
 
PBMCs from healthy donors were obtained from anonymized human leukocyte cones supplied 
by the National Blood Transfusion Service (NHS blood and transplantation, Tooting, London, 
UK). Human studies were conducted in accordance with the Helsinki Declaration and approved 
by the Institutional Review Board of Guy’s Hospital. (reference 09/H0707/86). Informed consent 
was obtained from all healthy donors prior to enrolment into the study. PBMC were isolated by 
Lymphocyte (PAA, Austria) density gradient centrifugation. CD4
+
CD25
+
 T cells were purified 
as described in paragraph 2 section 2.2.  The purity of CD4
+
CD25
+
 T cells was between 90-98%.  
 
2.2 Expansion of Treg cell lines for Drugs experiment 
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Healthy human CD4
+
CD25
+
 T cells, were plated at 1x10
6
/ml in X-Vivo 15 supplemented with 
5% HS and Rapamycin (100nM). Cells were initially stimulated with anti-CD3/CD28 beads 
(Invitrogen) at a bead: cell ratio of 1:1. IL-2 (1000IU/mL) was added at day 2 post-activation 
and replenished every 2 days.  Beads were removed by magnetic adherence every 7 days post-
activation and fresh anti-CD3/CD28 beads (1:1 ratio), Rapamycin, and IL-2 (1000 IU/ml) were 
added as well. Cells were cultured for 3 weeks prior to use. 
 
2.3 Drugs experiment 
 
After 21 days of expansion, beads were removed and different doses of immunosuppressive 
drugs, tacrolimus, mycophenolate mofetil and  methyl-prednisolone were tested one by one or in 
combination. Treg were activated with anti-CD3/CD28 beads (1:2 ratio) and IL-2 (20 IU/ml) in 
X-Vivo 15 plus the 3 drugs at different concentration. Tacrolimus range was 0-20 ng/ml, 
mycophenolate's one 0-2.5 ug/ml and for methylprednisolone the range was 0-4 ug/ml. Cells 
remained in culture for 5 days after that suppression ability and phenotype  were analyzed.  
 
2.4 Suppression assay 
 
For functional assay, cryopreserved responder T cells (Tresp cells) were thawed and labeled with 
CFSE as follows. Cells were washed twice in PBS, before being stained with 2.5 μM CFSE in 
PBS at 1x10
7
/mL. After 3 minutes at room temperature in the dark, the reaction was stopped by 
washing three times the cells with X-Vivo 15 supplemented with 5% HS. The cells were then 
resuspended in the same medium at the required concentration. In order to quantify differences 
in susceptibility to suppression, Tresp cells, labeled with CFSE, were cultured alone or at 
different ratios with Treg cells treated with drugs. In each case, the number of Tresp cells was 
kept constant (1x10
5
) and the number of Treg cells titrated down (Treg:Tres ratio= 1:1, 1:3 and 
1:10) in X-Vivo15 supplemented with 5% HS. The cells were stimulated with anti-CD3/CD28 
beads in U-bottom 96-well plates and incubated at 37°C, 5% CO2 for 5 days. To test the drugs 
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influence, suppression assays were setted up even in presence of drugs during the 5 days. After 
harvest, qualitative CFSE dilution was assessed by flow cytometry exluding dead cells using  
Live and Dead Fluorescent dying. The percentage of suppression was calculated using FlowJo 
software (TreeStarInc, USA). 
 
2.5 Antibodies for flow cytometry 
 
The following monoclonal antibodies were used: CD4-FITC/APC (OKT4), CD62L-FITC (Greg-
56) Live and Dead Fixable Yellow Dead Cell Stain kit from Invitrogen, UK; CD25-PE (4E3), 
CD152-PE (14D3), CD127-PE-Cy7 (eBioRDR5), GITR-APC (eBioAITR), ICOS-PE-Cy7 (ISA-
3), CD39-FITC (eBioA1), IFN--FITC (4S.B3), IL-17-PE (eBio64DEC17) and FOXP3-eFluor 
660 (PCH101) from eBioscience, USA; Integrin β7-PE-Cy5 (FIB504) from BD-Bioscience, UK; 
HLA-DR-APC (L243), CLA-FITC (HECA-452), CCR4-PerCP-Cy5.5 (TG6/CCR4) from 
Biolegend, USA. Appropriate isotype controls from mouse or rat were used. Prior to use, all 
mAbs were titrated using normal resting or activated PBMC to establish optimal staining 
dilutions. 
 
2.6 Cytometric beads array 
 
The concentration of cytokines was measured using a Cytokines cytometric bead array assay kit 
(BD Biosciences, San Diego, CA, USA) analysed on a BD Fortessa flow cytometer (BD 
Biosciences, San Diego, CA, USA). In this test we used three  populations of beads with 
different fluorescence intensity, giving a discrete peak on the flow cytometer. Each bead 
population was coated with a specific antibody against a human cytokine protein. This allowed 
the simultaneous measurement of different cytokines in a single multiplexed assay. The 
cytokines measured were human IL-10, IL-17 and INF-gamma. The beads, detection antibodies 
and samples or standards were incubated together, forming sandwich complexes, followed by 
aspiration into the flow cytometer for particle quantitation. Similarly to ELISA, in this assay 
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there is a direct correlation between fluorescence of coated antibodies and cytokine 
concentration. However, the main advantage of this kit is to require small sample volume to test 
many different cytokines in only one single assay.   
 
2.7 Statistical analysis 
 
Statistical analysis was carried out using GraphPad Prism software (GraphPad software Inc., 
USA). Parametric and non-parametric data were calculated as the mean±s.d. and median 
(interquartile range, IQR) respectively. For comparison of parametric and non-parametric data, t-
test, one- or two-way ANOVA with Bonferroni test comparison and Kruskal-Wallis test were 
used where appropriate. 
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3. Results 
 
3.1 Understanding the optimal dose for in vitro experiment 
 
To determine the direct effect of immunosuppressive regimen on Treg preparations, CD4
+
CD25
+
 
T cells were purified and in vitro expanded in the presence of rapamycin. Treg culture and 
expansion was performed as described in material and methods. Tacrolimus, methyl-
prednisolone and mycophenolate mofetil were tested as single therapeutic treatment or in 
combination on 21-day expanded Treg. To establish the right drug concentrations to replicate in 
vitro what happens in vivo with patients, a wide range of concentration, including the trough 
levels described in patient’s sera and reported in literature, were tested. Different range for 
tacrolimus (0-20 ng/ml) and mycophenolate mofetil (0-2.5 ug/ml) were used. Due to the lack of 
data on serum concentration of methylprednisolone in humans, a range of 0-4 ug/ml was used.  
The first experiment was the evaluation of cell viability in presence of the 3 drugs together 
(MIX) and separately. Cells were stimulated with anti CD3/CD28 coated beads and IL-2 (20 
IU/ml) and cultured for 3 days with the drug-range indicate above. Data in Figure 1 show the 
effect of the three different drugs on cell viability. Dose response curves were plotted to obtain 
the concentration of immunosuppressant leading to 50% of Treg viability. We calculated the half 
maximal effective concentration (EC50) of the single drugs inducing 50% survival in Treg 
activated for 3 days. Data showed that EC50 of tacrolimus, mycophenolate mofetil and 
methylprednisolone were 2 ug/mL, 1 ng/ml and 5 ug/ml respectively (Figure 1, Panels B-D).  
These concentrations were used in the setting of all in vitro experiments showed in this study. 
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Figure 1.  Dose response curves to derive the concentration of immunosuppressant. Ex vivo 
expanded Treg were activated with anti-CD3/CD28 coated beads (bead:cell ratio = 1:2) and IL-2 (20 
IU/ml) for 3 days in the presence of different concentration of drugs. Data in panel A show the Treg 
viability in presence of different concentrations of the 3 drugs together. Panel B,C and D show the 
concentration of tacrolimus, mycophenolate mofetil and methyl-prednisolone respectively leading to 
50% of Treg viability. 
 
 
3.2 Drug Effects on regulatory T cells expansion 
 
The presence of immunosuppressive treatment during cell therapy could also influence Treg 
proliferation. To this aim cells were activated with anti CD3/CD28 coated beads, IL-2 (100 
IU/ml) and cultured with the single treatments or the combination of drugs for 5 days to 
investigate the effect of tacrolimus, mycophenolate mofetil and methylprednisolone on their 
proliferative capacity. Cell counts at the end of culture showed that any immunosuppressive 
agent significantly reduced the proliferation of Treg (Figure 2, Panel A). The further analysis of 
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cell division, using Cell Trace Violet dilution profiles, revealed that Treg were more severely 
inhibited by tacrolimus, mycophenolate mofetil and the combination of drugs compared with 
methylprednisolone (Figure 2, Panel B). These conditions not only affected the final number of 
cells, but also the number of divisions that each cell had undergone (Figure 2 , Panel B and C).  
 
 
 
 
Figure 2.  Proliferative capacity of Treg in the presence of immunosuppressants. Panel A, total 
number of ex vivo expanded and rapamycin treated Treg activated with anti-CD3/CD28 coated beads 
(bead:cell ratio = 1:2) and IL-2 (100 IU/ml) and cultured for 5 days with only medium (CTR), single 
immunosuppressive agent at EC50 (TAC, MPA and mPR) or their combination (IS Mix) (n=9). Panel B, 
percentage of Treg determined by CTV dilution profile with more than three cycles of cell division 
determined in the same conditions described above (n=3). Data are presented as mean ± SD. Panel C, 
representative histograms showing the CTV dilitution profile of Treg cultured in the presence of drugs. * 
p<0.05, ** p<0.01; *** p<0.001. 
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3.3 Drug Effects on main regulatory T cells markers and homing receptor 
 
To better understand if the immunosuppressant regimen can affect Treg in vivo, the analysis 
proceeded evaluating the main Treg markers essential for their in vivo action. The first 
evaluation concerned  FOXP3 and CD25, followed by CD39, CTLA4, PD-L1, HLA-DR, GITR, 
ICOS and TGF-β (LAP). Cells were first incubated for 5 days in presence of  tacrolimus, 
mycophenolate mofetil, methyl prednisolone and the combination of 3 drugs together and then 
stained with the cognate antibody. Phenotype was evaluated using flow cytometry.  
A complete analysis of these markers revealed that cells did not change their expression 
retaining the same phenotype (Figure 3 Panel A). The same analysis showed that, in presence of 
immunosuppressants, the percentages of Treg expressing both FOXP3 and CD25 molecules did 
not change, however a reduction in the MFI for CD25 was observed (Figure 3B and C). 
 
Figure 3. Phenotype of Treg cultured with immunosuppressive agents. Panel A, Expression of typical 
Treg markers, panel A, on cells treated for 5 days with only medium (CTR), single immunosuppressive 
agent (TAC, MPA and mPR) or their combination (IS Mix) (n=5). Panel B, representative dot plots from 
9 different Treg preparations of FOXP3 and CD25 expression on Treg cultured 5 days with either only 
medium (CTR) or with the combination of 3 drugs (IS Mix). Panel C, mean fluorescence intensity of 
FOXP3 and CD25 on Treg treated in the same way described above 
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Rapamycin has the ability to modulate the expression of specific homing receptor. For this 
reason the expression of chemokine receptors like CCR4, CLA, CCR10 (skin-homing) integrin 
α4β7 and CXCR3 (gut/liver-homing) were evaluated following the in vitro treatment with drugs 
for 5 days. The expression of CCR4 and CLA was significantly reduced by tacrolimus and the 
combination of drugs. Similarly, in the same culture conditions Integrin α4β7 was up-regulated 
(Figure 4). This evidence suggests that tacrolimus alone or in combination with the other drugs 
might have an effect on homing capacity favoring Treg to traffic into the gut. 
 
 
Figure. 4 Expression of homing receptor in Treg cultured with immunosuppressive agents 
Expression of homing receptor on Treg treated for 5 days with only medium (CTR), single 
immunosuppressive agent (TAC, MPA and mPR) or their combination (IS Mix) (n=5) ** p<0.01; *** 
p<0.001. 
 
3.4 Immune suppressive treatment doesn't affect regulatory T cells suppressive ability 
 
Next step was the evaluation of functional Treg activity in vitro. As shown in previous reports178, 
rapamycin treated nTreg displayed a potent suppression of T cell proliferation. However, the 
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presence of immunosuppressive drugs could affect this suppressive ability. We tested whether 
pre-treatment of Treg with the combination of drugs or the single dose of tacrolimus, 
mycophenolate mofetil and methylprednisolone could impair suppressive function. For this 
reason Treg were activated with anti-CD3/CD28 coated beads (bead:cell ratio = 1:2) and IL-2 
(20 IU/ml) for 7 days in presence of the immunosuppressive drugs and then the suppressive 
ability was tested. As shown in figure 5, the suppressive ability of immunosuppressive drugs 
(alone or in combination) pre-treated Tregs were not significantly different from that of the 
untreated cells (CTR).  
 
 
Figure. 5  Effect of immunosuppressants on Treg suppressive ability. . Suppressive ability of Treg 
activated with anti-CD3/CD28 coated beads (bead:cell ratio = 1:2) and IL-2 (20 IU/ml) and pre-cultured 
for 7 days with only medium (CTR), single immunosuppressive agent (TAC, MPA and mPR) or their 
combination (IS Mix) (n=5). 
 
However, to better understand whether the suppressive function was affected in the presence of 
immunosuppressive drugs, we performed a suppression assay adding the single drugs or the 
combination of the drugs into the culture condition. To discriminate between the suppressive 
function of Treg and the anti-proliferative effect of drugs, we separately evaluated the 
proliferation of effector T cells in the presence of only drugs or drugs plus Treg at different ratio. 
Data in figure 6 show that although effector T cell proliferation is reduced by 
immunosuppressants, Treg were no affected in their function and preserved their full suppressive 
capacity  
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Figure. 6  Effect of immunosuppressants on Treg suppressive ability. Proliferative response of Teff 
cultured alone or in co-culture with Treg. Panel A B and C show ratio the  1:1, 1:3 and 1:10 Treg/Tresp 
ratio respectively in presence of different immunosuppressive agents as described above (n=5). 
 
3.5 Immunosuppressant drugs inhibit IL-10 production by Regulatory T cells 
 
Rapamycin inhibits proliferation of non-Treg cells, selectively favors the expansion of Treg and 
reduces the frequency of cells secreting pro-inflammatory cytokines such as IL-17 and IFN-γ178. 
A further analysis of the cytokine production profile of rapamycin treated Treg revealed that in 
this setting cells produce amount of IL-10 but nothing is known about the influence on cytokine 
production after immunosuppressant regimen. To this aim, rapamycin treated Treg were 
activated in the presence of tacrolimus, mycophenolate mofetil, methyl-prednisolone or their 
combination. After 5 days, culture supernatants were harvested and tested for the presence of 
cytokines. The amount of cytokine was normalized to the total number of cells at the end of 
culture. Data revealed that immunosuppressive treatments have no effect on IL-17 and IFN-γ 
production (Figure 7). However, the analysis of IL-10 production showed that tacrolimus and the 
combination of drugs strongly reduced this cytokine (Figure 7 panel C). This evidence suggests 
that although the suppressive capacity of Treg was not impaired, any treatment including 
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tacrolimus affects cytokine production including those that can lead to the recruitment and 
expansion of tolerogenic cells. 
  
 
 
Figure. 7  Effect of immunosuppressants on Treg cytokine production. Interleukin-17 (panel A), IFN-
 (panel B) and IL-17 (panel C) concentration of 5-day culture supernatant collected from Treg activated 
with anti-CD3/CD28 coated beads (bead:cell ratio = 1:2) and IL-2 (20 IU/ml) and treated with single 
immunosuppressive agent (TAC, MPA and mPR) or their combination (IS Mix) (n=3). * p<0.05 
 
 
 
4. Discussion 
 
Making the use of adoptive Treg therapy effective as a practical tool for preventing allograft 
rejection or for GvHD treatment requires supplemental considerations about the possible 
presence of concurrent immunosuppressive therapies. Administration of drugs which target and 
dampen excessive immune response can potentially prove harmful to adoptively-transferred 
Treg. However, it would be unethical and medically inappropriate to test the efficacy of infused 
Treg preparations in patients without support from conventional treatments, especially during 
phase I and II trials where Treg efficacy is not tested. As such, it is necessary to obtain pre-
clinical data showing the influence of a concurrent conventional therapy on Treg.  
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This study is mainly focused on tacrolimus, mycophenolate-mofetil and methyl-prednisolone, 
investigating their effect on Treg preparations that potentially can be infused in a program of 
adoptive cell therapy. Data show that immunosuppressive drugs partially influence the viability 
and the proliferative capacity of Tregs, however their phenotype and most of its suppressive 
ability is not altered. 
Studying the influence of immunosuppressive regimen on either in vitro or animal model is 
essential to establish the appropriate concentrations of drugs which simulate the outcome seen in 
humans, as closely as possible. Several studies have extensively reported the correct drug 
concentrations administered to mice coping the efficacy of immunosuppressive regimen in 
human transplantation. However, some considerations are required about the in vitro use of drug 
trough level to evaluate the impact of the treatment on human Treg.  
Several studies revealed that trough level may not correspond to the actual concentration active 
on cells in circulation. In fact, tacrolimus results mainly associated with erythrocytes (>70%), 
plasma proteins (>20%) and only a small fraction with lymphocytes (about 1%)181; 
mycophenolate is mainly bound to serum albumin (>97%) and only the free fraction is thought 
to be responsible for the immunosuppressive effect182.  
To this aim, a wide range of concentrations was tested (Figure 1) to establish the most 
appropriate to investigate the effect of immunosuppression on ex vivo expanded Treg.  
Data show that mycophenolate-mofetil, methyl-prednisolone and tacrolimus can, as either single 
treatment or in combination, decrease the number of Treg cell divisions (Figure 2).  
These results were in part expected considering the mechanism of action of immunosuppressant. 
The survival and suppressive activity of Tregs depend on an exogenous supply of IL-2183
,184. 
Tacrolimus, inhibiting calcineurin pathway, blocks IL-2 production from T cells and in this way 
explains part of the inhibitory effect on Tregs185. Previous studies provided only indirect 
evidence of this effect on Tregs showing calcineurin inhibitors to be potentially harmful186. 
Studies in animal model reported that Cyclosporins A, another calcineurin inhibitor, reduces 
Foxp3 expression in natural Tregs187
,184, diminishes the frequencies of CD4+CD25+Foxp3+ T 
cells188 and fails to support the differentiation of the highly suppressive CD4+CD25+CD27+ 
subset upon alloantigen stimulation139.  
Moreover, these data reveal that the detrimental effect of immunosuppressive regimen on Tregs 
might be extended to mycophenolate. In literature the effect of this drug on Tregs has not been 
extensively studied and data are controversial. Mycophenolate inhibits inosine 5'-monophosphate 
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dehydrogenase, a rate-limiting enzyme in the de novo synthesis of guanine nucleotides, thereby 
affecting DNA synthesis and cell replication of both conventional T cells and Tregs189. Data in 
literature support the idea that the influence of this drug on cell division may alter the expansion 
of antigen-specific Treg and prevent the settlement of a long term tolerance190. Similarly, Lim 
and collaborators showed that mycophenolate adversely affected the therapeutic effectiveness of 
adoptively-transferred Tregs, reducing the allograft survival in recipient mice from 21 to 16 
days191. Nevertheless, results in murine models are contrasting. Zeiser and collaborators 
demonstrated in a model of GvHD that the concurrent administration of freshly isolated Tregs 
and mycophenolate did not significantly inhibit Treg expansion, suppressive ability and 
eventually extended the overall survival184. 
Likewise the other drugs, in vitro data showed that methyl-prednisolone does not affect 
phenotype and function of Tregs (figure 3,5,6). Although the single treatment provided no 
additional benefit to cell preparation, at a certain dose, it influenced the expansion reducing cell 
division of Tregs. This result seems to be in conflict with data in literature. Many authors 
described positive effects of steroids in regard to the maturation and expansion of Tregs in 
autoimmune diseases. They have been described to amplify the IL2-dependent expansion of 
FOXP3+CD4+CD25+ T cells in vivo192, increase FOXP3 expression of Tregs in patients 
affected by asthma193 and restore the impaired suppressive function of Tregs in patients with 
relapsing multiple sclerosis194. However, both difficulties of in vivo steroid measurement and 
lack of data in literature showing the trough level of this medication make it hard to copy the 
effect of this treatment in vitro.  
In summary, this study shows that although immunosuppressive drugs partially influence the 
viability and the proliferative capacity of Tregs, their phenotype and most of its suppressive 
ability is not altered. Some concerns arise about the administration of high doses of 
immunosuppressive therapy during concurrent adoptive transfer of Tregs. Mainly in vitro data 
showed that the presence of drugs may reduce the proliferative capacity of Tregs and influence 
either the expression of homing receptors or tolerogenic cytokine production, such as IL-10. 
Thus, although many other factors in vivo can contribute to the success of a Treg therapy, the 
infusion of Tregs during the administration of the highest doses of immunosuppressants should 
be carefully considered or, at least, plan to infuse Tregs in multiple-dosing regimen. 
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General conclusion 
 
My research work as PhD student was principally devoted to the study of Treg as a tool for 
cellular therapy in patients undergoing organ or hemopoietic stem cell transplantation. 
Specifically, my work has been done at the Laboratory of Cellular Therapy of the Institute of 
Hematology “L. e A. Seràgnoli” of the University of Bologna and the laboratory of 
Immunoregulation at King’s College in London. 
Both laboratories are highly experienced in cell therapy and regulatory T cells characterization. 
This gave me the opportunity to exploit different backgrounds and knowledge to study the 
infusion of regulatory T cells to reduce/avoid graft rejection and for the treatment of GvHD  
In conclusion, it is possible to affirm that the use of expanded Tregs is necessary both in HD and 
patients, even when leukapheresis products are used as cell source. The high suppressive ability 
and the possibility to freeze the expanded fraction without problems will improve transplantation 
management, and allow the use of these cells for patients undergoing liver transplantation. 
Moreover, Treg expansion obtained in the presence of rapamycin confirms its importance as a 
drug improving Treg phenotype and function. The double-positive action of rapamycin, in vivo 
and in vitro, could be exploited to set up clinical trials in which this drug will be used for the ex 
vivo expansion and the in vivo retention of the infused cell product.  
Therapeutic strategies using Treg have to take into account that these cells not only need potent 
suppressive function, but also need appropriate tissue trafficking to enable contact with their 
target cells. Therefore, if the Treg are injected via a peripheral vein then it is important that they 
express molecules such as CD62L and CCR7 that are crucial for their migration to the lymph 
nodes and other chemokine receptors, e.g. CXCR3 for liver homing.  
Another important question concerns the number of cells needed for the infusion. To date, 
Treg therapy in the context of bone marrow transplantation has been very important to 
understand the tolerated and safe Treg doses. However, the first trials of Treg therapy in solid 
organ transplantation will need to start with a dose escalation study to assess the safety and 
tolerability of Tregs in this settings. In addition, whether a single injection or multiple injections 
are required is a matter of debate and may be determined in a Phase II efficacy study, where 
patient outcomes should also be measured. When a bigger number of patients will be analysed 
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the use of molecular diagnostic tools can help to assess the increased/reduced expression of 
either biomarkers of operational tolerance or rejection in patients receiving Treg therapy. 
Furthermore, phenotypic analysis of patient PBMCs, using flow cytometric analysis, can 
determine differences of the T cell compartment or cytokine profile as result of the adoptive cell 
therapy. 
As the infusion schedules are essential in clinical trials using Treg, the possibility of a single or 
double infusion and their timing should be carefully considered. The last section in this thesis 
showed how the presence of immunosuppressive drugs may reduce the proliferative capacity of 
Tregs, and how they may influence either the expression of homing receptors or the tolerogenic 
property of Tregs, for example trough the production of cytokine, such as IL-10.  Thus, although 
many other factors in vivo can contribute to the success of Treg therapy, the infusion of Tregs 
during the administration of the highest doses of immunosuppressants should be carefully 
considered or, at least, plan to infuse Tregs in multiple-dosing regimen. 
Together these studies contribute to the large body of literature that demonstrates the importance 
of using Treg cells as therapy in various transplant models. Although much work is still to be 
done in this regard, there is now concrete evidence to support the translation of this approach to 
the clinical arena.  
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